US.PFE · Pfizer

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.6008247422680415,
        "turnoverUsdM": 696.473192,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.PFE",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 22.9886,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.2,
      "take_profit_price": 25.4625,
      "target_multiplier": 1.6,
      "technical_strength": 1.45,
      "take_profit_percent": 5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.201649484536083,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 56,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 49,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 24.7845,
    "ma50": 25.484,
    "close": 24.25,
    "prevClose": 24.05,
    "avgVolume20": 51486307,
    "volumeRatio": 0.56,
    "changePercent": 0.83
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.015494137353433857,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.5543014872059527,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.5542340961090775,
      "volat_points": 0,
      "day_range_pct": 0.011958762886597902,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 56,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 56,
        "contribution": 2.8
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 10.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 68,
        "contribution": 10.2
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 68,
        "contribution": 6.8
      },
      {
        "raw": 11.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 39.33,
        "contribution": 11.8
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 49,
    "details": [
      "基本面分析總分: 2.8/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 10.2/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 6.8/10分",
      "技術信號分析總分: 11.8/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 2.8,
      "資金流": 8.4,
      "市場環境": 10.2,
      "情緒分析": 3,
      "技術信號": 11.8,
      "風險管理": 6.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.5,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 696.473192,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.PFE",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.9
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 720.9690033500002,
                "ma50": 713.79420164,
                "name": "QQQ",
                "close": 723.17999,
                "points": 2
              },
              "spy": {
                "ma20": 742.33551,
                "ma50": 740.3722033000001,
                "name": "SPY",
                "close": 751.71002,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.6008247422680415,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140853711,
                "url": "https://finnhub.io/api/news?id=032b398ac249490a7fc750ea6c2621e8c34c9262efc9813876f26250b4b531c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The U.S. Food and Drug Administration recently expanded approval for Pfizer’s IBRANCE, making it the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. This label expansion enhances the commercial and clinical importance of IBRANCE within Pfizer’s oncology franchise at a time when the company faces pressure from upcoming patent expirations and weaker COVID-related revenues. We’ll now examine how this new maintenance indication for...",
                "category": "company",
                "datetime": 1783617353,
                "headline": "Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative?"
              },
              {
                "id": 140841826,
                "url": "https://finnhub.io/api/news?id=a50c9d8e99c45c2a53d51a07cc9a2b03e0777db6416ad70b2cf23437194d96c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Recent interest in Pfizer (PFE) has been driven by U.S. regulators approving IBRANCE as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. This approval opens an additional use for this oncology drug. See our latest analysis for Pfizer. Despite the positive IBRANCE news and a long dividend track record, Pfizer’s recent share price performance has been weak. The stock is down over the past month and quarter, while the 1-year total...",
                "category": "company",
                "datetime": 1783523499,
                "headline": "Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval?"
              },
              {
                "id": 140841828,
                "url": "https://finnhub.io/api/news?id=60d1603a05d70f51082c263012eb67bd5d6759dfcb6f247c03823811a356be76",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1783515605,
                "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140840567,
                "url": "https://finnhub.io/api/news?id=65ea2b78b443e26fb34a56819fcdbdd1cc66f1a856204922ccf8ae1b23686e00",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) is one of the dividend stocks picked by financial media as investors ask whether dividend stocks are tax-efficient. On June 24, Pfizer said its board declared a $0.43 third-quarter dividend on the company’s common stock, payable September 1 to holders of record at the close of business on July 24. Pfizer also […]",
                "category": "company",
                "datetime": 1783514929,
                "headline": "How Pfizer’s (PFE) Dividend Record Separates Tax Treatment From Business Momentum"
              },
              {
                "id": 140827916,
                "url": "https://finnhub.io/api/news?id=25504993a6eb4381da6b086591a4e419f4975efc5a39a72aaefcabf94b74db77",
                "image": "",
                "source": "Fintel",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1783410864,
                "headline": "HSBC Downgrades Pfizer (PFE)"
              },
              {
                "id": 140825405,
                "url": "https://finnhub.io/api/news?id=5e30e52a144784a67ba65e26b4eb031695633a604daf470c9ac8781ea2ebe603",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) concluded the recent trading session at $23.72, signifying a -2.47% move from its prior day's close.",
                "category": "company",
                "datetime": 1783374303,
                "headline": "Pfizer (PFE) Stock Sinks As Market Gains: Here's Why"
              },
              {
                "id": 140821151,
                "url": "https://finnhub.io/api/news?id=6a00b12582e1165c091f4ba20eacc947aebfa4bf209e1432e7fae8fe2af51de2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's IBRANCE has received new FDA approval as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. The approval covers use of IBRANCE in combination with trastuzumab and endocrine therapy for patients with this subtype of breast cancer. The decision is based on results from the Phase 3 PATINA trial. For investors watching Pfizer (NYSE:PFE), this approval adds a fresh clinical milestone to a stock that has faced pressure in...",
                "category": "company",
                "datetime": 1783347059,
                "headline": "Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer"
              },
              {
                "id": 140815808,
                "url": "https://finnhub.io/api/news?id=ea4577ed58144b2199935239e64da810b772973dadbf2ed89bbc8b35f3d0935e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy, according to hedge funds. On June 24, the US Food and Drug Administration approved the use of Pfizer Inc. (NYSE:PFE)’s Ibrance in combination with trastuzumab as a maintenance option for patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction treatment. […]",
                "category": "company",
                "datetime": 1783291882,
                "headline": "Pfizer Inc. (PFE): A Top Dividend Stock to Buy According to Hedge Funds amid Ibrance FDA Milestone"
              }
            ],
            "raw_source": [
              {
                "id": 140855845,
                "url": "https://finnhub.io/api/news?id=b3d351adc993be520435759189d72560b105017da985670db5e2dac92e23e062",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing.",
                "category": "company",
                "datetime": 1783628781,
                "headline": "Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump"
              },
              {
                "id": 140853711,
                "url": "https://finnhub.io/api/news?id=032b398ac249490a7fc750ea6c2621e8c34c9262efc9813876f26250b4b531c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The U.S. Food and Drug Administration recently expanded approval for Pfizer’s IBRANCE, making it the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. This label expansion enhances the commercial and clinical importance of IBRANCE within Pfizer’s oncology franchise at a time when the company faces pressure from upcoming patent expirations and weaker COVID-related revenues. We’ll now examine how this new maintenance indication for...",
                "category": "company",
                "datetime": 1783617353,
                "headline": "Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative?"
              },
              {
                "id": 140853712,
                "url": "https://finnhub.io/api/news?id=b2bd8c6450a444d35fdf90da15015ace9f69d206c8068603d591af895b7998ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Jim Cramer stared down a stock yielding 7% and sitting near its 52-week low, and still would not tell viewers to buy it. On the July 7 episode of CNBC’s Mad Money, a caller from Orland Park, Illinois pitched Pfizer as an income-and-value setup, and Cramer conceded the case looked tempting. He landed on a ... ‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend",
                "category": "company",
                "datetime": 1783614359,
                "headline": "‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend"
              },
              {
                "id": 140853484,
                "url": "https://finnhub.io/api/news?id=a37245c725bdaa7038adeca694577bae64e2a1096e408d1811dd4be0d93626e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker: insurers, device makers, biotech, and Big Pharma. It has returned 21.61% over the past year and 159.84% over ten years. If the reason ... Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%",
                "category": "company",
                "datetime": 1783613908,
                "headline": "Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%"
              },
              {
                "id": 140852126,
                "url": "https://finnhub.io/api/news?id=018b9f7253bc4e17d4c43637f9d4ef486eb81a27b4c5665faefb42064eb3b9b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.",
                "category": "company",
                "datetime": 1783609118,
                "headline": "Make Your AMGN Shares Pay You 8.7% While You Hold Them"
              },
              {
                "id": 140850812,
                "url": "https://finnhub.io/api/news?id=276e65ac7c5991a39aa9ec7a3758acb5f3ce4bad2e75fab780b4fe5f46f7d0c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.",
                "category": "company",
                "datetime": 1783602824,
                "headline": "ABBV Leads Its Peer Group. You Pay For That"
              },
              {
                "id": 140851010,
                "url": "https://finnhub.io/api/news?id=baad14237a296505b0f589808df734d3452f7c8dbc22fee130edb502eb4c71f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing.",
                "category": "company",
                "datetime": 1783601672,
                "headline": "Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump"
              },
              {
                "id": 140851011,
                "url": "https://finnhub.io/api/news?id=ba16631660d3a48a5ae531367822bcf906cdafae0322973ac498035a39a0af61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.",
                "category": "company",
                "datetime": 1783601100,
                "headline": "AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction"
              },
              {
                "id": 140851012,
                "url": "https://finnhub.io/api/news?id=9d098d0c35c7da1da47ea2eb69d092c9fa0c3e5f1c16e510a0016b77aa5c7dc5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "TORONTO, July 09, 2026--BenchSci, a leading provider of AI software for biopharma research and development, today announced the appointment of Dr. Mikael Dolsten, M.D., Ph.D., as Chairman of its Board of Directors, effective June 2026 — the first Chairman role in the company's history. Dr. Dolsten joined BenchSci's board as a director in July 2025, a year after retiring as Chief Scientific Officer and President of Pfizer Research & Development, where he could have taken a board seat at nearly an",
                "category": "company",
                "datetime": 1783598400,
                "headline": "BenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board"
              },
              {
                "id": 140851514,
                "url": "https://finnhub.io/api/news?id=ba024cdd9895c7708abe3ca98f213636ae50da1e97d62de266bad2fd79a3848f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2197698139/image_2197698139.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Alnylam Pharmaceuticals stands to benefit from the unexpected Phase III failure of Ionis/AstraZeneca’s eplontersen. Read why ALNY stock is a buy.",
                "category": "company",
                "datetime": 1783593830,
                "headline": "Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook"
              },
              {
                "id": 140850358,
                "url": "https://finnhub.io/api/news?id=840cbddb211ad3a61dbdba03223eb2cf874f8da5b0b48f025699b494ac5f7406",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256411028/image_2256411028.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly.",
                "category": "company",
                "datetime": 1783586769,
                "headline": "Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry"
              },
              {
                "id": 140848108,
                "url": "https://finnhub.io/api/news?id=83802d7c0c6cf8398ae3af9cf033877b0a4aec73cbd5ee80e3f87882e6d45d45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. ...",
                "category": "company",
                "datetime": 1783573620,
                "headline": "JPMorgan resets LLY stock target on drug demand"
              },
              {
                "id": 140853229,
                "url": "https://finnhub.io/api/news?id=fce005d26d622395102680065e12d43aeffbb9a90be304e815e5badc41c3e34d",
                "image": "https://image.cnbcfm.com/api/v1/image/108198691-1757936194403-gettyimages-2221649488-Astrazeneca_Office_Building_in_Shanghai.jpeg?v=1760116750&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.",
                "category": "company",
                "datetime": 1783568048,
                "headline": "AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse"
              },
              {
                "id": 140845452,
                "url": "https://finnhub.io/api/news?id=83b05d7ea9501ebcffd979ee1e3ecb29f7a2f8c1cad68e0317792ab69e882a07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Income investors watching the calendar have a narrow window this week. Three of the market’s most widely held high-yield names are about to lock their next payment rosters, and the buy-by deadlines are close enough that a delayed brokerage order could push readers a full quarter down the line before the next check clears. The ... 3 High-Yield Dividends That Pay You Soon (But You Must Act Quickly)",
                "category": "company",
                "datetime": 1783541247,
                "headline": "3 High-Yield Dividends That Pay You Soon (But You Must Act Quickly)"
              },
              {
                "id": 140843362,
                "url": "https://finnhub.io/api/news?id=597f4902dfd05c08eeacaf56c3d2203bd898010321778f32442a1e1312d5a219",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri",
                "category": "company",
                "datetime": 1783529860,
                "headline": "Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says"
              },
              {
                "id": 140843488,
                "url": "https://finnhub.io/api/news?id=9d90ff2551d2d5004257cbb593ff48f0e618ac0992bc59c659cc691556e0a037",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.",
                "category": "company",
                "datetime": 1783528080,
                "headline": "BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth"
              },
              {
                "id": 140843489,
                "url": "https://finnhub.io/api/news?id=93b440e72e137679f65118af120552914cdb9db6b72a76c74aef27d6d4cb31a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BridgeBio Pharma's Attruby sales are surging, but can growth keep justifying its premium valuation amid execution risks and rising costs?",
                "category": "company",
                "datetime": 1783527900,
                "headline": "Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead"
              },
              {
                "id": 140843490,
                "url": "https://finnhub.io/api/news?id=2ad20f95b9249086624408e0edba856ea10e7dda35497055c104f4c59f3173dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.",
                "category": "company",
                "datetime": 1783527780,
                "headline": "BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts"
              },
              {
                "id": 140841778,
                "url": "https://finnhub.io/api/news?id=c1d9e054f88af7cc76ad45c92c50beba49c8aebc5a78167930dc9e5fb87ef4c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.",
                "category": "company",
                "datetime": 1783524984,
                "headline": "The Wide Divide Ahead For Eli Lilly Stock"
              },
              {
                "id": 140841826,
                "url": "https://finnhub.io/api/news?id=a50c9d8e99c45c2a53d51a07cc9a2b03e0777db6416ad70b2cf23437194d96c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Recent interest in Pfizer (PFE) has been driven by U.S. regulators approving IBRANCE as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. This approval opens an additional use for this oncology drug. See our latest analysis for Pfizer. Despite the positive IBRANCE news and a long dividend track record, Pfizer’s recent share price performance has been weak. The stock is down over the past month and quarter, while the 1-year total...",
                "category": "company",
                "datetime": 1783523499,
                "headline": "Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval?"
              },
              {
                "id": 140841809,
                "url": "https://finnhub.io/api/news?id=9115f15dbec4ba6eb3628f98f8d259cf39b7bdba9b0b5a2a9d5cf1c3e7ac4b64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The S&P 500 keeps climbing, up nearly 9% year to date, and yet a handful of large-cap dividend payers are trading like the bull market forgot they exist. That is exactly where opportunity hides in July. If you have $1,000 to put to work, three NYSE-listed names stand out on valuation, cash flow, and payout ... 3 Absurdly Cheap Dividend Stocks to Buy With $1,000 in July",
                "category": "company",
                "datetime": 1783520798,
                "headline": "3 Absurdly Cheap Dividend Stocks to Buy With $1,000 in July"
              },
              {
                "id": 140841828,
                "url": "https://finnhub.io/api/news?id=60d1603a05d70f51082c263012eb67bd5d6759dfcb6f247c03823811a356be76",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1783515605,
                "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140840567,
                "url": "https://finnhub.io/api/news?id=65ea2b78b443e26fb34a56819fcdbdd1cc66f1a856204922ccf8ae1b23686e00",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) is one of the dividend stocks picked by financial media as investors ask whether dividend stocks are tax-efficient. On June 24, Pfizer said its board declared a $0.43 third-quarter dividend on the company’s common stock, payable September 1 to holders of record at the close of business on July 24. Pfizer also […]",
                "category": "company",
                "datetime": 1783514929,
                "headline": "How Pfizer’s (PFE) Dividend Record Separates Tax Treatment From Business Momentum"
              },
              {
                "id": 140840466,
                "url": "https://finnhub.io/api/news?id=ba0edb8678292f7637ad16b2934dae337c3ef3760794d05a61f7e4f34e6b582c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.",
                "category": "company",
                "datetime": 1783513980,
                "headline": "3 Cancer Stocks to Watch as Oncology Innovation Accelerates"
              },
              {
                "id": 140842902,
                "url": "https://finnhub.io/api/news?id=1a2f71857ee982240ad2bedd9c9f798519fe4faf467d1463e02f441c36f7b81c",
                "image": "https://image.cnbcfm.com/api/v1/image/108332131-17835223421783522339-47036321107-1080pnbcnews.jpg?v=1783522341&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "Scott Rechler, chairman and CEO of RXR, joins 'Squawk on the Street' to discuss the buckling high-rise in Manhattan, converting former office buildings into residences and more.",
                "category": "company",
                "datetime": 1783508496,
                "headline": "RXR CEO Scott Rechler on office conversion push"
              },
              {
                "id": 140845356,
                "url": "https://finnhub.io/api/news?id=9aded0979b5fc1c01d4a491dae253a32f0cb4a540e202ec9f8e10ba2748b1604",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "JP Morgan  analyst Chris Schott   maintains Pfizer (NYSE:PFE) with a Neutral and lowers the price target from $30 to $28.",
                "category": "company",
                "datetime": 1783508280,
                "headline": "JP Morgan Maintains Neutral on Pfizer, Lowers Price Target to $28"
              },
              {
                "id": 140836418,
                "url": "https://finnhub.io/api/news?id=e1fa3e19cc21dbace8a889bebf619d15744ea5c1152d1b2f2e0c8b90f04edfad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "They may not remain cheap for too much longer.",
                "category": "company",
                "datetime": 1783464600,
                "headline": "2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now"
              },
              {
                "id": 140835477,
                "url": "https://finnhub.io/api/news?id=b03613ad52a2bf852782ae88316b0d4f5ca9f28d287f041d33fb5612ca8121d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Finding stocks with generous dividends isn’t easy these days, and with packaged food giant Conagra recently getting demoted from the S&P 500, Pfizer is now the highest yielding stock in the benchmark index.  The drug company, which has made quarterly payouts more than 80 straight years, is certain to get a lot of attention from dividend hunters.  Pfizer’s high yield reflects investors’ trepidation over the stock.",
                "category": "company",
                "datetime": 1783452780,
                "headline": "2 Healthcare Stocks to Buy for Their Dividends—and Why Pfizer Isn’t One of Them"
              },
              {
                "id": 140835353,
                "url": "https://finnhub.io/api/news?id=c4f382b5352bbe5ca224d50764aeb31d6d4bba886603869762d997d1bc75054d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Construction at  Pfizer’s  former headquarters in Manhattan was halted Tuesday because of crumbling floors and other structural issues.  The problems with the building’s renovation, which the company sold about eight years ago for conversion to apartments, are a metaphor of sorts for Pfizer stock, which began Tuesday with the highest yield in the  index, at more than 7%.  Pfizer stock, which is up 1.6% to $24.10 Tuesday, has been the worst performer among its large-cap U.S. peers during 2026 and over the past 10 years.",
                "category": "company",
                "datetime": 1783452120,
                "headline": "Former Pfizer Building Is Crumbling—Just as the Stock Has"
              },
              {
                "id": 140842604,
                "url": "https://finnhub.io/api/news?id=25b9737c32659b118e6d06e5fd552407615007fb05e58b3082830c3625d38b4e",
                "image": "https://image.cnbcfm.com/api/v1/image/108331765-3ED1-MM-A-070726.jpg?v=1783463497&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "CNBC's Jim Cramer discusses the day's market action, the stocks he's watching and more.",
                "category": "company",
                "datetime": 1783451536,
                "headline": "I find it surprising that so much money was flowing into the hyperscalers: Cramer"
              },
              {
                "id": 140833487,
                "url": "https://finnhub.io/api/news?id=1c6e56e01538f2129725a1a2245a56483aab3fa381ee0e06751530a6743d1d38",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for the market.",
                "category": "company",
                "datetime": 1783447501,
                "headline": "These S&P500 stocks are the most active in today's session"
              },
              {
                "id": 140832866,
                "url": "https://finnhub.io/api/news?id=cab4113429911de971a850c6643e196f8c2937ce65e17b8eb11e2d422699e893",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance. For retail investors scanning for value, the sub-$30 shelf in healthcare currently offers exposure to a pending strategic ... 3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now",
                "category": "company",
                "datetime": 1783444791,
                "headline": "3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now"
              },
              {
                "id": 140833114,
                "url": "https://finnhub.io/api/news?id=f756293627432faf14cb488eca0a7282ce6023709b0717ee9832737f3076b676",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A 7% dividend yield will grab your attention, but be sure to read the fine print.",
                "category": "company",
                "datetime": 1783440300,
                "headline": "Opinion: Pfizer's Dividend Is Riskier Than You Might Think"
              },
              {
                "id": 140831295,
                "url": "https://finnhub.io/api/news?id=3f5c10eed8e8606ed043e3df2f6b863e7bcce6f39900fce931d599a7f1c0dcb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.",
                "category": "company",
                "datetime": 1783429260,
                "headline": "Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?"
              },
              {
                "id": 140830195,
                "url": "https://finnhub.io/api/news?id=9d80ef43b5d93185e9562bcdf1c88c58365a62710c1dcc2c31a9557085e49539",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Healthcare has become Wall Street’s bargain bin in 2026, and value hunters are starting to pay attention. Drug pricing reform, patent cliffs and post-COVID-19 hangovers have crushed multiples across Big Pharma, but the wreckage has created opportunities in two cash-generative franchises trading at single-digit forward earnings multiples. Heading into July, Novo Nordisk and Pfizer stand ... 2 Dirt Cheap Healthcare Stocks to Buy in July",
                "category": "company",
                "datetime": 1783427427,
                "headline": "2 Dirt Cheap Healthcare Stocks to Buy in July"
              },
              {
                "id": 140827916,
                "url": "https://finnhub.io/api/news?id=25504993a6eb4381da6b086591a4e419f4975efc5a39a72aaefcabf94b74db77",
                "image": "",
                "source": "Fintel",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1783410864,
                "headline": "HSBC Downgrades Pfizer (PFE)"
              },
              {
                "id": 140825405,
                "url": "https://finnhub.io/api/news?id=5e30e52a144784a67ba65e26b4eb031695633a604daf470c9ac8781ea2ebe603",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) concluded the recent trading session at $23.72, signifying a -2.47% move from its prior day's close.",
                "category": "company",
                "datetime": 1783374303,
                "headline": "Pfizer (PFE) Stock Sinks As Market Gains: Here's Why"
              },
              {
                "id": 140824417,
                "url": "https://finnhub.io/api/news?id=186fff17d3fd8c74d0ea37961a030197361df88d1472c2d1cb324314c6a059a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.",
                "category": "company",
                "datetime": 1783369384,
                "headline": "What Eli Lilly Stock Said When It Had Too Much Business"
              },
              {
                "id": 140822960,
                "url": "https://finnhub.io/api/news?id=7f6dadda73094a707158c540764e15eb0531a6e697ba7ba97279949834966388",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Let's have a look at what is happening on the US markets on Monday. Below you can find the most active S&P500 stocks in today's session.",
                "category": "company",
                "datetime": 1783361100,
                "headline": "Explore the S&P500 index on Monday and find out which stocks are the most active in today's session."
              },
              {
                "id": 140822583,
                "url": "https://finnhub.io/api/news?id=a1cfc708dc4e87791be5070950f211a0e8b9d48ad9ed86bfaee9b1c7d09f3ad9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.",
                "category": "company",
                "datetime": 1783353300,
                "headline": "Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?"
              },
              {
                "id": 140834366,
                "url": "https://finnhub.io/api/news?id=abc10786c5d0f4f18de6845914e601f93e69006be4c5f969c9910cea38526873",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/06/Pharma-Giant-Joins-Initiative.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer was downgraded to Hold as analysts cited delayed pipeline catalysts, management changes and reduced near-term re-rating potential.",
                "category": "company",
                "datetime": 1783347270,
                "headline": "Pfizer's Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount"
              },
              {
                "id": 140821151,
                "url": "https://finnhub.io/api/news?id=6a00b12582e1165c091f4ba20eacc947aebfa4bf209e1432e7fae8fe2af51de2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's IBRANCE has received new FDA approval as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. The approval covers use of IBRANCE in combination with trastuzumab and endocrine therapy for patients with this subtype of breast cancer. The decision is based on results from the Phase 3 PATINA trial. For investors watching Pfizer (NYSE:PFE), this approval adds a fresh clinical milestone to a stock that has faced pressure in...",
                "category": "company",
                "datetime": 1783347059,
                "headline": "Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer"
              },
              {
                "id": 140819320,
                "url": "https://finnhub.io/api/news?id=35f52776660d9ec36474180a714ebba89a58bab560a35354ffec23746c014381",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you ... Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More",
                "category": "company",
                "datetime": 1783338748,
                "headline": "Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More"
              },
              {
                "id": 140819912,
                "url": "https://finnhub.io/api/news?id=b5d2bd20e0a76d685d7676d5181354c92bbb779edc1b0cc1076343be0a7f6da6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/628093148/image_628093148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they lag AI names. Click for the picks.",
                "category": "company",
                "datetime": 1783331728,
                "headline": "My Top 5 Pharma Stocks Wall Street Ignores"
              },
              {
                "id": 140823076,
                "url": "https://finnhub.io/api/news?id=10e3149e30354dcea9534bcd86613720b4e2e814833ae2d782d9195f342a0b69",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   reiterates Pfizer (NYSE:PFE) with a Neutral and maintains $27 price target.",
                "category": "company",
                "datetime": 1783329790,
                "headline": "Cantor Fitzgerald Reiterates Neutral on Pfizer, Maintains $27 Price Target"
              },
              {
                "id": 140821477,
                "url": "https://finnhub.io/api/news?id=743d43840259a92e2562df1f97f04a8d16633d283ef9fc14e9a2cbe9695563d6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/06/Analysts-Adjust-Progressive-Targets.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Top analysts changed outlook on top names. Visit analyst ratings page for complete view. See opinions on HBAN, PFE, DAL, MTB, BRO stocks.",
                "category": "company",
                "datetime": 1783322347,
                "headline": "This M&T Bank Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday"
              },
              {
                "id": 140823078,
                "url": "https://finnhub.io/api/news?id=41fc41ff5f2568092ca2829a24bef00ad5f930bb3460014eeb28c3b7860c6a66",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "HSBC  analyst Rajesh Kumar   downgrades Pfizer (NYSE:PFE) from Buy to Hold and lowers the price target from $32 to $28.",
                "category": "company",
                "datetime": 1783317195,
                "headline": "HSBC Downgrades Pfizer to Hold, Lowers Price Target to $28"
              },
              {
                "id": 140815808,
                "url": "https://finnhub.io/api/news?id=ea4577ed58144b2199935239e64da810b772973dadbf2ed89bbc8b35f3d0935e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy, according to hedge funds. On June 24, the US Food and Drug Administration approved the use of Pfizer Inc. (NYSE:PFE)’s Ibrance in combination with trastuzumab as a maintenance option for patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction treatment. […]",
                "category": "company",
                "datetime": 1783291882,
                "headline": "Pfizer Inc. (PFE): A Top Dividend Stock to Buy According to Hedge Funds amid Ibrance FDA Milestone"
              },
              {
                "id": 140820581,
                "url": "https://finnhub.io/api/news?id=d78c036b50e519b565344311a0d3db62f47be1f8e694fcce308d14cfbc7f99d2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/05/Elizabeth-Warren.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while also challenging TrumpRx's impact on drug costs.",
                "category": "company",
                "datetime": 1783260507,
                "headline": "Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States"
              },
              {
                "id": 140804781,
                "url": "https://finnhub.io/api/news?id=ed6b59910ce862c95cd40b12aaf34010202640c1a9fb28002c12aa3b3cb403ad",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/831753552/image_831753552.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Explore 8 “safer” S&P 500 dividend dogs (VICI, VZ, T, F & more) with strong cash-flow coverage and 2027 upside forecasts—see which to buy now.",
                "category": "company",
                "datetime": 1783129139,
                "headline": "Buy In July: 8 IDEAL 'Safer' S&P 500 DiviDogs"
              },
              {
                "id": 140795063,
                "url": "https://finnhub.io/api/news?id=bdb4fef361ff4d2af9d2c5f525ac4c9fcc523e6e39e215c39c20e90739f4da54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Could this be the secret to Pfizer's rebound strategy?",
                "category": "company",
                "datetime": 1783027200,
                "headline": "Pfizer's CEO Says His Company Has a \"Very Big Balance Sheet\" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant"
              },
              {
                "id": 140793956,
                "url": "https://finnhub.io/api/news?id=574d1b3d49bb567c3c862b31bfc81d8f93243913911962c6bf4d9b1bbec3b8f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "(Bloomberg) -- President Donald Trump made more than 21,000 securities trades in his first year back in office, often in intense bursts tied to market events he created.Most Read from BloombergExxon to Change Name for First Time in Decades After RedomicileMeta Is Planning a Cloud Business to Sell AI Computing PowerGermany Rejects Trump’s Demands for NATO Loyalty to WashingtonRussia Indicates Ukraine Fired Long-Range Ballistic MissileKrafton Agrees to Pay ‘Subnautica 2’ Bonuses as Developer’s CEO",
                "category": "company",
                "datetime": 1783015123,
                "headline": "Trump Financial Disclosure Shows 21,000 Trades in 2025"
              },
              {
                "id": 140792959,
                "url": "https://finnhub.io/api/news?id=ee6da6462659dfa08361afe62be1aecd7ac76b797f01f38b6a14f5d8d0d35fbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting game for investors.",
                "category": "company",
                "datetime": 1783013373,
                "headline": "JNJ Stock Management Sees A Breakout, The Market Sees A Standoff"
              },
              {
                "id": 140800457,
                "url": "https://finnhub.io/api/news?id=999e37fcb927fdc13d87b729a5a78234e62f08588956532f4477a7d73d9c09e3",
                "image": "https://image.cnbcfm.com/api/v1/image/108330302-17830266361783026634-46916365950-1080pnbcnews.jpg?v=1783026635&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "CNBC's \"Fast Money\" team discusses the tech trade, market rotation and more with Michael Farr, chairman at FarrCrest Capital.",
                "category": "company",
                "datetime": 1783012424,
                "headline": "FarrCrest Capital's Farr on the market rotation and tech trade"
              },
              {
                "id": 140795898,
                "url": "https://finnhub.io/api/news?id=1c3d61baa20c671c5661468dfe34f7a12b64ad2ebd08913e49f50389c3362e54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Haleon has struck a five-year partnership with Microsoft as it looks to expand its AI transformation using Microsoft's Copilot.",
                "category": "company",
                "datetime": 1783010117,
                "headline": "Haleon Just Struck a Five-Year Deal With Microsoft. Here Is What It Means for Haleon Stock."
              },
              {
                "id": 140792961,
                "url": "https://finnhub.io/api/news?id=56ace9e8f9a3601c5c52f7e264cce2da28a30e17b535a2b0bb8be19b8729298e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...",
                "category": "company",
                "datetime": 1783008180,
                "headline": "House committee investigates Merck, AbbVie over China trials"
              },
              {
                "id": 140791366,
                "url": "https://finnhub.io/api/news?id=a60b16d0d67885632b53f8b7db33b97bba6bda6dfda573e80f8a5eb74776eba9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Passive income is the paycheck that arrives whether you show up or not. Wages depend on a functioning employer, a healthy economy, and the continued willingness of both to keep the seat warm. Dividend income depends on a company writing a check every 90 days, and for a handful of blue chips, that check has ... $500 a Month in These Stocks Will Generate $6,700 in Passive Annual Income",
                "category": "company",
                "datetime": 1783004573,
                "headline": "$500 a Month in These Stocks Will Generate $6,700 in Passive Annual Income"
              },
              {
                "id": 140790254,
                "url": "https://finnhub.io/api/news?id=d8ca063f560a9c7bb37395914ee6bff0ffe0d2dbeaa98009574e9b77ccb49a83",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Ascendis Pharma stock surged on Yorvipath’s blockbuster launch and Yuviwel FDA approval. Read the latest analysis on ASND stock here.",
                "category": "company",
                "datetime": 1782985473,
                "headline": "Ascendis Pharma: Behind The Stock Surge"
              },
              {
                "id": 140791120,
                "url": "https://finnhub.io/api/news?id=233b7ac50abe0742971f1567c47077b52c4ff2476e0bf977d51d0666f74aff41",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "https://t.co/sFqLF8qeSI",
                "category": "company",
                "datetime": 1782983924,
                "headline": "WHO Director-General Ghebreyesus Says He Considers The Cruise Ship-Linked Hantavirus Outbreak To Be Over"
              },
              {
                "id": 140789093,
                "url": "https://finnhub.io/api/news?id=b49372047c0d1d5515be747da8f25332a49f8c785d5b1b52fd84517f85f27b5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.",
                "category": "company",
                "datetime": 1782982344,
                "headline": "2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Turn Down"
              },
              {
                "id": 140780769,
                "url": "https://finnhub.io/api/news?id=1c2f4fbfc651fef953e889a20660b791537068fdd23bbf2136ac930d38984e55",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.",
                "category": "company",
                "datetime": 1782915600,
                "headline": "Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy?"
              },
              {
                "id": 140791144,
                "url": "https://finnhub.io/api/news?id=296da59202b329e94eb30e441728d2248e767c13e8d3682da006e1acea6629a2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/01/Eli-Lilly-and-Co.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Innovent and Eli Lilly sign a China commercialization deal for Verzenios, expanding patient access while Lilly retains manufacturing.",
                "category": "company",
                "datetime": 1782911358,
                "headline": "Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China"
              },
              {
                "id": 140779454,
                "url": "https://finnhub.io/api/news?id=c366bf379bb1092d995dc3ee85c652cdae1e7867cc61435044d2b9afd2abe1ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.",
                "category": "company",
                "datetime": 1782907980,
                "headline": "Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage"
              },
              {
                "id": 140779533,
                "url": "https://finnhub.io/api/news?id=6e09e9087825e36132bb224a4238441552d6736155157f3046fa4af746d2cc59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.",
                "category": "company",
                "datetime": 1782896745,
                "headline": "Doctor-turned-dealmaker reveals his M&A playbook"
              },
              {
                "id": 140777411,
                "url": "https://finnhub.io/api/news?id=f5b17266fc9bbceea8685aa3f3c9b9257f05c08a3b85c9c3756ac095e2969f8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer stock is trading in a range where recent returns have been weak over three years, yet the broader valuation checks still lean cheap and suggest the current share price may not fully reflect the company’s fundamentals. Over the past 3 years, Pfizer has delivered a total return that is down about 21%, which shows how much sentiment has cooled since its pandemic peak. The push into oncology and obesity treatments, including recent IBRANCE progress and weight loss drug development, can...",
                "category": "company",
                "datetime": 1782880257,
                "headline": "Is Pfizer (PFE) Stock Undervalued Despite Mixed Oncology Progress?"
              },
              {
                "id": 140777800,
                "url": "https://finnhub.io/api/news?id=461cbb5b7f58f3554a1150c46860a6a3927cbe341e5f7319b8faf7361fc080af",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1300120223/image_1300120223.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "My bullish options sub-portfolio brought 60% annualized ROI since inception, crushing the S&P 500 or some options ETFs. Read more on the strategy here.",
                "category": "company",
                "datetime": 1782875826,
                "headline": "Like My Stock Portfolio, My Bullish Options Portfolio Crushed The Benchmarks"
              },
              {
                "id": 140776272,
                "url": "https://finnhub.io/api/news?id=9c0fa14ab3deddccd179895680d521a7dbabed6cab62d54c701591501aa28659",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) closed at $24.08 in the latest trading session, marking a -1.19% move from the prior day.",
                "category": "company",
                "datetime": 1782855906,
                "headline": "Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors"
              },
              {
                "id": 140775328,
                "url": "https://finnhub.io/api/news?id=d653bc8b5b5d5d4be7060d73b710c383755317accbe5314353287dcbde08f386",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Nike's (NKE) fiscal fourth-quarter revenue slipped year-over-year, while the sportswear company's ea",
                "category": "company",
                "datetime": 1782853676,
                "headline": "Nike Fourth-Quarter Revenue Slips as Expected Tariff Refunds Boost Earnings"
              },
              {
                "id": 140775329,
                "url": "https://finnhub.io/api/news?id=14ef91b5d318a3c405bb605dba0e995057b6f61b6c65b2bb5e6acb2d627d85de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Nike stock (NKE) is moving lower in Tuesday's extended-hours trading after reporting mixed results for the sportswear brand's fiscal fourth quarter: while earnings topped estimates, revenue declined 1.1% year-over-year. Morningstar senior equity analyst David Swartz discusses what he was expecting from the earnings release and how Nike's performance is lining up with CEO Elliott Hill's turnaround strategy.",
                "category": "company",
                "datetime": 1782853061,
                "headline": "Nike turnaround is taking longer than CEO Elliott Hill expected: Analyst"
              },
              {
                "id": 140775242,
                "url": "https://finnhub.io/api/news?id=02b91b29d4d6866e764fad5d9b5d883e4c856174563540aa0f7ce0aaf8483c13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.",
                "category": "company",
                "datetime": 1782851051,
                "headline": "Why Is JNJ Stock Defying The Market’s Daily Mood Swings?"
              },
              {
                "id": 140773944,
                "url": "https://finnhub.io/api/news?id=1ced7bb16d986dbc5d54041d714c9881556f83d762c9209f572bdb225bda7c90",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Stay informed about the most active stocks in the S&P500 index on Tuesday's session. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1782842700,
                "headline": "Looking for the most active stocks in the S&P500 index on Tuesday?"
              },
              {
                "id": 140773408,
                "url": "https://finnhub.io/api/news?id=8fb61dd33fcbbb335ced32a5c70432f74c400c32d98a99a75027e78a574e6083",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Volatility can lower the cost of entry into businesses that throw off real cash, even as investors recognize that a low share price alone is no guarantee of a bargain. Heading into the back half of 2026, three blue-chip names trading well below the $45 mark stand out for the same reason: predictable cash flows, ... 3 Dirt-Cheap Stocks Under $45 Built to Outperform in a Volatile Market",
                "category": "company",
                "datetime": 1782838057,
                "headline": "3 Dirt-Cheap Stocks Under $45 Built to Outperform in a Volatile Market"
              },
              {
                "id": 140773471,
                "url": "https://finnhub.io/api/news?id=b60fbb2c0ce1fb45c8387013f66392ad1bc0f85028dedac5e289199b0afaea57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...",
                "category": "company",
                "datetime": 1782836340,
                "headline": "Merck, AbbVie probed by US lawmakers over China clinical trials: report"
              },
              {
                "id": 140773586,
                "url": "https://finnhub.io/api/news?id=c6e0476e59592a8485924005735032a5f4d376a379161dc1a98916283d89ca89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "I keep buying Pfizer (NYSE:PFE) every time my brokerage cash builds up, and I am not slowing down. The market is treating this company like a value trap because COVID revenue is rolling off. I am treating it like a cash machine that just bought itself three extra years of patent life on one of ... Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat",
                "category": "company",
                "datetime": 1782836145,
                "headline": "Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat"
              },
              {
                "id": 140773587,
                "url": "https://finnhub.io/api/news?id=b14d8a4a4df572ec5dd36dfce74c378ba4cad7af2cf47b716a9de2ed4398ade2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.",
                "category": "company",
                "datetime": 1782832200,
                "headline": "CRMD's Growth Story Expands Beyond DefenCath Into New Trends"
              },
              {
                "id": 140773588,
                "url": "https://finnhub.io/api/news?id=101ff63855217fab4b5803347ce8c248c613db66414f4095edbfe0a3476860c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.",
                "category": "company",
                "datetime": 1782832020,
                "headline": "Is CRMD Stock a Buy Now After Strong Growth and New Risks?"
              },
              {
                "id": 140773589,
                "url": "https://finnhub.io/api/news?id=1f5cd482979b12c032cde218cf3a01b6bbe8baa4f5c4638d4e7163e6b4796234",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.",
                "category": "company",
                "datetime": 1782831840,
                "headline": "CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path"
              },
              {
                "id": 140774085,
                "url": "https://finnhub.io/api/news?id=f82c597c7b0224650e59ddbedd837ca5b0705ff6b4b1e9f677918cb5b2ffc780",
                "image": "",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1782829958,
                "headline": "Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate"
              },
              {
                "id": 140772056,
                "url": "https://finnhub.io/api/news?id=5c33c56afc99cbd67b46aaafc8b0fc05e55af3c6785fb391097adb51275ff502",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Few large-cap dividends generate as much skepticism as Pfizer (NYSE:PFE). The stock trades at $24.37, and the COVID franchise erosion has been brutal, with Comirnaty down 59% and Paxlovid down 63% in Q1 2026. Yet the dividend keeps coming. I want to know if that 7.27% yield is a gift or a warning. The Dividend ... This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios",
                "category": "company",
                "datetime": 1782827441,
                "headline": "This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios"
              },
              {
                "id": 140771834,
                "url": "https://finnhub.io/api/news?id=8dde04ddcab7fa50ac6d1569beb5d10e4aa9a73a0a05a6d7b7b82f65248f4c2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "It could prove to be a case of better later than never for the healthcare giant.",
                "category": "company",
                "datetime": 1782825600,
                "headline": "Why Pfizer Could Prove to Be an Underrated GLP-1 Stock"
              },
              {
                "id": 140781955,
                "url": "https://finnhub.io/api/news?id=ba88807cf0ccddc6b8093e62c38c465ae13314ab73df98fc19ad55fdd94af86e",
                "image": "https://image.cnbcfm.com/api/v1/image/108297266-1777127244178-gettyimages-2272978539-anotherday208771149_942vh80l.jpeg?v=1777127293&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "Nike was expected to report another quarter of declining sales as the sneaker giant struggles to regain strength under its turnaround strategy.",
                "category": "company",
                "datetime": 1782820801,
                "headline": "Nike results top estimates even as China sales drop 12%; retailer expects $986 million tariff refund"
              },
              {
                "id": 140772368,
                "url": "https://finnhub.io/api/news?id=3baa0b6d8130b52153c4c742a502edc285b76c9502f66aef88dfb9d8fc3d6dd9",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "- Reuters ",
                "category": "company",
                "datetime": 1782813049,
                "headline": "U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials"
              },
              {
                "id": 140772314,
                "url": "https://finnhub.io/api/news?id=e10497ea38e4fbad71eb7072d597a29bb43582fc3c78ed5ce80d21a5cf7c2964",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Vertex Pharmaceuticals Incorporated offers predictable CF cash flows and pipeline catalysts in pain, hematology & renal (Pove for IgAN). Click for this VRTX update.",
                "category": "company",
                "datetime": 1782810196,
                "headline": "Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech"
              },
              {
                "id": 140781725,
                "url": "https://finnhub.io/api/news?id=cf3205279fea17c3900bbcdfba512aa037db7930700fa3d1e1c2b96b21bcb244",
                "image": "https://image.cnbcfm.com/api/v1/image/108328650-17828230041782823001-46866699601-1080pnbcnews.jpg?v=1782823003&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the FDA's selection of seven companies for its PreCheck Pilot Program, concerns over drug trials in China, and more",
                "category": "company",
                "datetime": 1782808861,
                "headline": "Dr. Scott Gottlieb on concerns over drug trials in China"
              },
              {
                "id": 140765416,
                "url": "https://finnhub.io/api/news?id=95a85c6616a1501f68624ef59ae95118582b4bae62be2a70cc74e23ab2cfc456",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.",
                "category": "company",
                "datetime": 1782758026,
                "headline": "AbbVie Stock Rockets 17% With 5-Day Winning Streak"
              },
              {
                "id": 140765518,
                "url": "https://finnhub.io/api/news?id=f47fa2418e158cde89d0b88a181d4e606ef22f6cd16af378367b14c1b226f051",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Is PFE a good stock to buy? We came across a bullish thesis on Pfizer Inc. on r/ValueInvesting by Dismal-Cancel4958. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $25.08 as of June 22nd. PFE’s trailing and forward P/E were 19.15 and 8.50 respectively according to Yahoo Finance. Pfizer […]",
                "category": "company",
                "datetime": 1782756478,
                "headline": "Is Pfizer Inc. (PFE) A Good Stock To Buy Now?"
              },
              {
                "id": 140765417,
                "url": "https://finnhub.io/api/news?id=54fca79a72ef6ab10f321f3b9a76224d1539a3dba8e92484bc7fdf1e835ee63d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.",
                "category": "company",
                "datetime": 1782754652,
                "headline": "Should You Chase The Breakout In Eli Lilly Stock?"
              },
              {
                "id": 140766217,
                "url": "https://finnhub.io/api/news?id=488e3e2c93c13800334fb14b1876f80a9a8aa7c1ac7f6c72ca089bd9f5f3ff34",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241146296/image_2241146296.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Big pharma’s patent cliff may be overstated: layered IP, incremental innovation, and smart licensing extend exclusivity and growth. Click here to read more.",
                "category": "company",
                "datetime": 1782752400,
                "headline": "Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It"
              },
              {
                "id": 140764004,
                "url": "https://finnhub.io/api/news?id=157b2da2f44df7243da25e74d43797d4e8b9ef60702fa15a9eb2006a9b5c901c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.",
                "category": "company",
                "datetime": 1782748982,
                "headline": "3 No-Brainer Dividend Stocks to Buy Right Now"
              },
              {
                "id": 140762434,
                "url": "https://finnhub.io/api/news?id=3bd33bc43ad83cf95c1ba3fa393f3a7a5daf9983af4be995282d55213e8608bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on. Bristol Myers Squibb: ... 66 With $1.3 Million. Here Are 3 Hidden Gems to Target",
                "category": "company",
                "datetime": 1782744663,
                "headline": "66 With $1.3 Million. Here Are 3 Hidden Gems to Target"
              },
              {
                "id": 140761650,
                "url": "https://finnhub.io/api/news?id=664a954c77cfefc1492f5e524a365b2a4e1910993b0d04c60e2185af5850d751",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The companies will work together to launch and scale new biotechnology companies using AI to accelerate drug development. SAN FRANCISCO, CA / ACCESS Newswire / June 29, 2026 /Edison Scientific and Population Health Partners (PHP) today announced a ...",
                "category": "company",
                "datetime": 1782740160,
                "headline": "Edison Scientific and Population Health Partners Partner to Build the Next Generation of Biotech Companies"
              },
              {
                "id": 140767422,
                "url": "https://finnhub.io/api/news?id=8ced992d1efdb7f6e266aef06459bf23cbb551553af8eaad63e60ccb64201b26",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer Canada ULC announced today that Health Canada has, under priority review and Project Orbis initiative, approved PADCEV (enfortumab vedotin for injection), in combination with pembrolizumab, as neoadjuvant",
                "category": "company",
                "datetime": 1782724116,
                "headline": "Pfizer Canada Secures Health Canada Approval For PADCEV Plus Keytruda In Muscle Invasive Bladder Cancer Under Project Orbis Initiative"
              },
              {
                "id": 140767423,
                "url": "https://finnhub.io/api/news?id=591002cc4bd83edc5c949151b2f8690192c9d6b785006c4c7bcb115385c950ca",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "-Reuters",
                "category": "company",
                "datetime": 1782705761,
                "headline": "Pfizer GLP-1 Drug And Innovent Biologics' Mazdutide Both Pass Preliminary Review For China Medical Insurance Drug List"
              },
              {
                "id": 140756682,
                "url": "https://finnhub.io/api/news?id=c55ec2fb5b366bfaebbeac0cbe66e29baa998993e97c1e86d82282d6350c828d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) is among the Best Healthcare Stocks. On June 23, Reuters reported that Pfizer Inc. (NYSE:PFE) ‘s Chief International Commercial Officer, Alexandre de Germay, said China has moved ahead of Europe in pharmaceutical innovation and drug development. De Germay commented that China now has “40% of all clinical studies in oncology” globally. He pointed […]",
                "category": "company",
                "datetime": 1782676681,
                "headline": "China surpassing Europe in Drug Innovation and Development, Pfizer Inc. (PFE) Executive says"
              },
              {
                "id": 140753167,
                "url": "https://finnhub.io/api/news?id=887e86e0c9b1d6cde20805b357ab6a52ccc51f71be3adcf5f62c562f4176c4a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Things are going from bad to worse for the pharmaceutical giant.",
                "category": "company",
                "datetime": 1782636600,
                "headline": "A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?"
              },
              {
                "id": 140749131,
                "url": "https://finnhub.io/api/news?id=58d735f04b5e1767f15093feb5110a7efe82a5116aca477d1291aeebd71dfb5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) has been dismissed as a defendant in a major federal lawsuit alleging generic drug price fixing. The court found there was not enough evidence to support claims of Pfizer's involvement in alleged collusion. The dismissal removes a legal overhang tied to long running litigation involving multiple generic drugmakers. Pfizer is a large global pharmaceutical company with a portfolio spanning prescription medicines, vaccines, and other healthcare products. For investors...",
                "category": "company",
                "datetime": 1782590822,
                "headline": "Pfizer (PFE) Dismissed From Generic Drug Price Fixing Lawsuit"
              },
              {
                "id": 140748090,
                "url": "https://finnhub.io/api/news?id=bb1f2a447e30ca3a27dbda3c907feef88c8d98b145a71c6ff2f64357c1535571",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.",
                "category": "company",
                "datetime": 1782588900,
                "headline": "Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now"
              },
              {
                "id": 140747188,
                "url": "https://finnhub.io/api/news?id=84fe3bf8cd60ac0e147c1c71bbb398d5fac66f76d26e3bb395ffc30683760aee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The sizable yield comes with a concerning footnote. Just look at the rest of the story.",
                "category": "company",
                "datetime": 1782576420,
                "headline": "Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends"
              },
              {
                "id": 140746249,
                "url": "https://finnhub.io/api/news?id=2326d0015cb7cd459a2b10cb2e71b4f1dee0923ac72d78bd2ff2635e7ebf97ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "With just 30 components, the Dow's exclusivity is built on industry leadership, which SpaceX has in spades.",
                "category": "company",
                "datetime": 1782570000,
                "headline": "Alphabet Is Joining the Dow Jones Industrial Average. 3 Surprising Reasons Why SpaceX Could Be Next."
              },
              {
                "id": 140746796,
                "url": "https://finnhub.io/api/news?id=fe15595f4953f27cc4b58c74d5c83ff2d2864a24e30ace17bb82dd2bdc1827df",
                "image": "https://image.cnbcfm.com/api/v1/image/108327725-17825072231782507209-46792477115-1080pnbcnews.jpg?v=1782507222&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "CNBC’s “Closing Bell Overtime” team discusses where the best opportunities are in pharma and biotech stocks with Evan Seigerman, head of healthcare research at BMO Capital Markets.",
                "category": "company",
                "datetime": 1782493286,
                "headline": "Why BMO's Siegerman says Merck is a top healthcare stock pick"
              },
              {
                "id": 140737993,
                "url": "https://finnhub.io/api/news?id=4ec7a0224ab0405979874fb3b438152890cd9bb8fada3b210159c9b7b2acaaad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The company's post-Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer look.",
                "category": "company",
                "datetime": 1782489808,
                "headline": "AbbVie Stock's Growth Story Has One Question Mark"
              },
              {
                "id": 140738042,
                "url": "https://finnhub.io/api/news?id=f8b316ddbf026bf067b5337eb62e61e0db952dee0b18064b45a8553ecf61881b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?",
                "category": "company",
                "datetime": 1782489673,
                "headline": "Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?"
              },
              {
                "id": 140739246,
                "url": "https://finnhub.io/api/news?id=47ec2a2209086a44ad157e6195ed8a0ffc0e3023569ffaf896991b26b1a9e44d",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1782480916,
                "headline": "4 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140736565,
                "url": "https://finnhub.io/api/news?id=58e6ef77fa4cfcc4711c8add341e85a063222d60fcf5f4dcee1c794f38c63f6b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
                "category": "company",
                "datetime": 1782478804,
                "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140737078,
                "url": "https://finnhub.io/api/news?id=8a0ee8ed09b1c9cc93901aba4ae3ce74cfb2c6a2d282cd515cdd310326975c69",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1257962304/image_1257962304.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Novo Nordisk A/S outlook: 2026 guidance warns revenue/profit declines as GLP-1 competition, pricing pressure & patent risks rise. Click for this NVO update.",
                "category": "company",
                "datetime": 1782478606,
                "headline": "Novo Nordisk: 3 Key Reasons The 'Buy The Dip' Thesis Is Flawed"
              },
              {
                "id": 140736885,
                "url": "https://finnhub.io/api/news?id=c0217598157e48224a3bfcf8450e05b884f0f68481c674e4e88619762afa3cbd",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2227945708/image_2227945708.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Pfizer continues to focus on its portfolio of drugs. Read how the company may navigate the patent cliff. Click here to read more on PFE.",
                "category": "company",
                "datetime": 1782477050,
                "headline": "Pfizer: Why Being Bullish Makes Sense Despite The Patent Cliff"
              },
              {
                "id": 140735402,
                "url": "https://finnhub.io/api/news?id=f66c19d5851ef96aeb67410ad66a2550bdf938cfb681795097a82b14267d6a57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Keybanc said Nike’s outlook is further clouded by growing uncertainty around operations in China and EMEA, as well as management transition.",
                "category": "company",
                "datetime": 1782476085,
                "headline": "NKE Stock Heads For Its Worst Week In Nearly Three Months – Wall Street Sees Encouraging Signs But Not Enough To ‘Remain Optimistic’"
              },
              {
                "id": 140736167,
                "url": "https://finnhub.io/api/news?id=18dfba5fc950aa37163bb9405733dd2df82a6772c61a81c3962d6ef34c02e99c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/26/Kuala-Lumpur--Malaysia---August-28--2024.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "KeyBanc downgraded Nike, citing slower-than-expected progress in its turnaround strategy and mounting competition from rival brands.",
                "category": "company",
                "datetime": 1782471234,
                "headline": "Nike Analyst Turns Bearish As Recovery Takes Longer Than Expected"
              },
              {
                "id": 140736545,
                "url": "https://finnhub.io/api/news?id=e72951be3fab838af9d6e2b36b35b21e637b3de8d8e76c23e51c14cb43d98755",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's CFO joins Nike, Wendy's hires Potbelly Sandwiches' CFO, Airwallex's new CFO boomerangs back to the company and more.",
                "category": "company",
                "datetime": 1782468600,
                "headline": "CFOs On the Move: Week ending June 26"
              },
              {
                "id": 140735129,
                "url": "https://finnhub.io/api/news?id=8f1bf596ce182e56e350eee0da5f22dee126d24c8d2f65b0f0da933c699ddae7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260722103/image_2260722103.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Jazz Pharmaceuticals' shares are in the distribution phase because Zepzelca failed to show a survival benefit over irinotecan. See why JAZZ stock is downgraded to hold.",
                "category": "company",
                "datetime": 1782465751,
                "headline": "Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)"
              },
              {
                "id": 140734904,
                "url": "https://finnhub.io/api/news?id=ba405cbb5351c150f0bceddf11fff95636a06e4fa33d4125056aa50956322117",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2250056975/image_2250056975.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Beam Therapeutics could have a moat around its business due to Risto-cel showing competitive efficacy. See why BEAM stock is downgraded to a hold.",
                "category": "company",
                "datetime": 1782463200,
                "headline": "Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade)"
              },
              {
                "id": 140733834,
                "url": "https://finnhub.io/api/news?id=6e884268f60dc7bbfe252cddcfbf41ce848ef06d9e43f4d565dffe4b99d91ba6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2252678470/image_2252678470.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Broad market bearishness prompts defensive buys in oversold defense stocks, high-yield Pfizer, and cash reserves. Read more here.",
                "category": "company",
                "datetime": 1782449898,
                "headline": "2026 Mid-Year Outlook: Big Market Risks, AI And Memory Mania Concerns, And My Top Bargain Stock Picks"
              },
              {
                "id": 140732541,
                "url": "https://finnhub.io/api/news?id=9dbc5921a466cd5b616de3a9dfa755139b685b8709005d1290eeed7828cfd1b8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2222953404/image_2222953404.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Led by Ozempic and Wegovy, glucagon-like peptides (GLP-1s) have become a global phenomenon, with one in eight US adults currently taking one.",
                "category": "company",
                "datetime": 1782434700,
                "headline": "Ozempic Sat Unused For Decades Because Invention Is Not Enough"
              },
              {
                "id": 140729431,
                "url": "https://finnhub.io/api/news?id=a39ed9ec0df153be4a5560c97317f1cb46625a61f77315297ea5701c0fb1f3d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.",
                "category": "company",
                "datetime": 1782422101,
                "headline": "AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140728921,
                "url": "https://finnhub.io/api/news?id=fcac8da501a17a5651003393ca48302280cd8ae678c43ab4bff0f570cbb43af5",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2280346058/image_2280346058.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Long-term bond yields persist. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. Read which ones here.",
                "category": "company",
                "datetime": 1782404914,
                "headline": "4 'Safer' Dividend Buys Out Of Barron's 23 June Better Bets Than T-Bills"
              },
              {
                "id": 140728256,
                "url": "https://finnhub.io/api/news?id=fe09615738f720b79148f002449a84295f6cc57536303c77cbec46d50464156b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1438509823/image_1438509823.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Pfizer announced that a late-stage trial in lung cancer for a Seagen-derived ADC, sigvotatug vedotin, has failed. Phase I results had looked so good that Pfizer skipped right to Phase III.",
                "category": "company",
                "datetime": 1782402000,
                "headline": "Antibody-Drug Conjugates: Not Quite Worked Out Yet"
              },
              {
                "id": 140725720,
                "url": "https://finnhub.io/api/news?id=a346fb06878946df84b361ac6cf8e147819535aaa49b566713e29cf2e293446c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.",
                "category": "company",
                "datetime": 1782396240,
                "headline": "MRK Gets EU Nod for Keytruda & Padcev Combination in Bladder Cancer"
              },
              {
                "id": 140725603,
                "url": "https://finnhub.io/api/news?id=7eed288d9717bb09c3523d4b46516d2e4ac00b07a3dacab5765a363039e56cc9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a",
                "category": "company",
                "datetime": 1782394800,
                "headline": "Nike Joins Alphabet, Walmart in Hiring a CFO From the Outside"
              },
              {
                "id": 140724628,
                "url": "https://finnhub.io/api/news?id=e60e0d53c29cae6a62405f595805fcb0a85ab2d24a77ac35334cdf053e7f339c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Watch Fireside Chat Below, or Click HERE: Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge […]",
                "category": "company",
                "datetime": 1782392426,
                "headline": "REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan"
              },
              {
                "id": 140724686,
                "url": "https://finnhub.io/api/news?id=3361a0a7b4ccc1e72977775e4ffc632d99d62e954ebc12ae4c74bd0ed2f7c320",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.",
                "category": "company",
                "datetime": 1782390350,
                "headline": "2 Large-Cap Stocks to Target This Week and 1 We Find Risky"
              },
              {
                "id": 140723395,
                "url": "https://finnhub.io/api/news?id=609a25ce2e0f4bbd1b5bd5a1d6037695c65c2a37610f36e5ad5f79028ba10c7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "David Denton will replace Matthew Friend, who will remain at the company until 4 September to assist with the handover.",
                "category": "company",
                "datetime": 1782381349,
                "headline": "Nike appoints David Denton as new CFO"
              },
              {
                "id": 140724395,
                "url": "https://finnhub.io/api/news?id=4103ee9f0605d35d70f4749bf7d87232b08923f7eebce92623e47d35efaab78e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1146642361/image_1146642361.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "GSK stock outlook: 3.46% dividend yield, 2026 core EPS growth guided at 7%–9%, and Exdensur as a new asthma growth driver—read the analysis now.",
                "category": "company",
                "datetime": 1782380178,
                "headline": "Is GSK Quietly Becoming An Oncology Powerhouse"
              },
              {
                "id": 140731356,
                "url": "https://finnhub.io/api/news?id=aa3525c0fb18a5fd113633afb6ce3e1157d95f6e54530511a835b24f51b193a0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/25/Pfizer-logo-on-building.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "The FDA approves Pfizer's Ibrance regimen for HR+, HER2+ metastatic breast cancer maintenance after positive Phase 3 data.",
                "category": "company",
                "datetime": 1782380154,
                "headline": "FDA Expands Pfizer's Ibrance Label For Frontline Maintenance In Advanced Breast Cancer"
              },
              {
                "id": 140722016,
                "url": "https://finnhub.io/api/news?id=bcba874a87eaf9b1605821af0c7c94d78003086f5c84e652e7471f6167149a80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Retail traders cited Novo CEO Mike Doustdar’s comment that Novo could afford a $20B, $30B or $40B deal if it was “worth it.”",
                "category": "company",
                "datetime": 1782360885,
                "headline": "VKTX Stock Eyes Best Week In 2 Years: Retail Bulls Bet Q3 Obesity Data Could Put Novo, Big Pharma In Buyout Play"
              },
              {
                "id": 140720753,
                "url": "https://finnhub.io/api/news?id=030e27a5f3f5bb6ddc88c90e5e2dc650644ae0162f47767456f01ecbdb9041dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Earlier this week, Pfizer reported that its Phase 3 SigVie-002 trial of sigvotatug vedotin in previously treated non-squamous non-small cell lung cancer failed to show a statistically significant overall survival benefit over docetaxel in the overall population, while the U.S. FDA approved IBRANCE as a maintenance option for adults with HR-positive, HER2-positive advanced or metastatic breast cancer following induction therapy. Together, the mixed lung cancer data and the expanded IBRANCE...",
                "category": "company",
                "datetime": 1782347067,
                "headline": "Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative"
              },
              {
                "id": 140719888,
                "url": "https://finnhub.io/api/news?id=c04456c560c0532bb35271516a3934ebc5f369f16c3003312d61f7d085c6d66d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In the most recent trading session, Pfizer (PFE) closed at $24.04, indicating a -2.75% shift from the previous trading day.",
                "category": "company",
                "datetime": 1782337503,
                "headline": "Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know"
              },
              {
                "id": 140719889,
                "url": "https://finnhub.io/api/news?id=74f57877388b04a9b6767d8234c77bab01d6e4bc9fb7a6075074fb6c7e8cb17c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The U.S. Food and Drug Administration approved the use of Ibrance as maintenance treatment for adults with a specific type of advanced or metastatic breast cancer on Wednesday.",
                "category": "company",
                "datetime": 1782335687,
                "headline": "PFE Stock Continues To Drop As Lung Cancer Trial Disappointment Overshadows Ibrance Win"
              },
              {
                "id": 140717105,
                "url": "https://finnhub.io/api/news?id=b7cfe107aa2c3f4b3e050b65526dd6c0bda369a729df618d57d4367a17ec29ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, June 24, 2026--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2026 dividend on the company’s common stock, payable September 1, 2026, to holders of the Common Stock of record at the close of business on July 24, 2026.",
                "category": "company",
                "datetime": 1782330720,
                "headline": "Pfizer Declares Third-Quarter 2026 Dividend"
              },
              {
                "id": 140717005,
                "url": "https://finnhub.io/api/news?id=3f59a4c983b77042aa9b5c7b418ca5680832404b8328b939e755f4f4f4ef0e61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie's post-Humira growth story has been a triumph, but the single drug driving that narrative is showing the first hint of a slowdown.",
                "category": "company",
                "datetime": 1782329550,
                "headline": "The Number That Could Test AbbVie Stock"
              },
              {
                "id": 140717006,
                "url": "https://finnhub.io/api/news?id=da9777eae917ebc72757f3d43721e42f0531becf4d27de3d6fdc76687f5d650a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% a",
                "category": "company",
                "datetime": 1782329529,
                "headline": "Sector Update: Healthcare Stocks Advance Late Afternoon"
              },
              {
                "id": 140717108,
                "url": "https://finnhub.io/api/news?id=40dee38a02476a7aded9d15b58e8a7fc6ad7dd167a4b8c263876ebd9102b84b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "With an annual dividend yield of 6.96%, Pfizer Inc. (NYSE:PFE) is included among the 12 Best S&P 500 Stocks to Buy for Dividends. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company’s global portfolio includes medicines and vaccines, as well as many of the world’s […]",
                "category": "company",
                "datetime": 1782328907,
                "headline": "Pfizer (PFE) Reaffirms FY 2026 Outlook Amid Leadership Change"
              },
              {
                "id": 140717109,
                "url": "https://finnhub.io/api/news?id=d0d586e1d50b1054b03cb37eed92a88a4f1c34e348e5735354f9f3564e0d40cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "(Updates with Pfizer's response in the last two paragraphs.) Pfizer (PFE) has been dismissed as a",
                "category": "company",
                "datetime": 1782327177,
                "headline": "Update: Market Chatter: Pfizer Dismissed From US States' Lawsuit on Generic Drug Price Fixing"
              },
              {
                "id": 140717110,
                "url": "https://finnhub.io/api/news?id=6d39b897383a63be746d8a09c0b164392da329aad0b31a51128a28bf59ef9678",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, June 24, 2026--Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCE® (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer (MBC) following induction treatment. The approval is based on positive results from the",
                "category": "company",
                "datetime": 1782324600,
                "headline": "FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance"
              },
              {
                "id": 140716127,
                "url": "https://finnhub.io/api/news?id=cc23f177b9eb10d8d1f062c3a7caebdc78ae144a13b2c30d3697f5f93499bff0",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Let's have a look at what is happening on the US markets on Wednesday. Below you can find the most active S&P500 stocks in today's session.",
                "category": "company",
                "datetime": 1782324300,
                "headline": "Most active S&P500 stocks in Wednesday's session"
              },
              {
                "id": 140718434,
                "url": "https://finnhub.io/api/news?id=45d0a2b04312d1e24fe6dcbbc2131fb99717aa46ad05037b249ed1c30eedcb4c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The sports apparel giant is turning to new financial leadership as it looks to make more progress with its “Win Now” turnaround strategy.",
                "category": "company",
                "datetime": 1782315492,
                "headline": "Nike lands Pfizer CFO with $7.3M ‘new hire’ cash award"
              },
              {
                "id": 140714105,
                "url": "https://finnhub.io/api/news?id=dbc3e890db9e6fc9615b8d06c8fee17724c0a91c41a3d86def357b23c99177f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Nike Inc (NYSE:NKE, XETRA:NKE) has announced that David Denton will join the company as executive vice president and chief financial officer effective August 17, succeeding Matthew Friend, who will remain with the company through September 4 to support the transition. According to the...",
                "category": "company",
                "datetime": 1782312840,
                "headline": "Nike names former Pfizer CFO David Denton as finance chief"
              },
              {
                "id": 140714106,
                "url": "https://finnhub.io/api/news?id=acd0f1b7bcc9d4c56e1258a9e1da016840394c41519bbdc116c4efd93858f9d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Nike names David Denton, a former Pfizer and CVS Health executive, as its next chief financial officer. The company also provides updated guidance.",
                "category": "company",
                "datetime": 1782308460,
                "headline": "Can a Former Pfizer Executive Catalyze Nike’s Sluggish Turnaround?"
              },
              {
                "id": 140713986,
                "url": "https://finnhub.io/api/news?id=6b2d5bb04fcbf51ab82f11b501253c8b8d69b6e7d698de88c929d248f98e45a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Lilly's GLP-1 leadership, expanding pipeline and strong earnings growth outlook make it a standout pick over Pfizer despite its premium valuation.",
                "category": "company",
                "datetime": 1782305940,
                "headline": "LLY or PFE: Which Drugmaker Offers the Stronger Growth Story?"
              },
              {
                "id": 140731357,
                "url": "https://finnhub.io/api/news?id=6b9c585578da94d8bbabe131bc5805f78ce193b58e35f9f79199c26ce3876e64",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-palbociclib-trastuzumab-or-without-pertuzumab-and-endocrine-therapy-maintenance",
                "category": "company",
                "datetime": 1782304936,
                "headline": "Pfizer's Palbociclib In Combination With Trastuzumab Receives FDA Approval For Treatment Of Metastatic Breast Cancer"
              },
              {
                "id": 140712965,
                "url": "https://finnhub.io/api/news?id=6e9cf5817f3e5713dfaa098bc3f307f643874270d2e3d7b8766f4e69764f2af1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "David Denton, who has led Pfizer's finances since 2022, will take over as Nike's chief financial officer on Aug. 17",
                "category": "company",
                "datetime": 1782304532,
                "headline": "Nike names Pfizer CFO David Denton to replace Matthew Friend"
              },
              {
                "id": 140712966,
                "url": "https://finnhub.io/api/news?id=bfb5cf3a0e656e309528c23f75f13ce0ced6166b3313baebb5605516a0fca7a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Nike names David Denton, a former Pfizer and CVS Health executive, as its next chief financial officer, and provides updated guidance.",
                "category": "company",
                "datetime": 1782302940,
                "headline": "Nike’s New Finance Chief Isn’t a Retail Insider—He’s Coming From Pfizer"
              },
              {
                "id": 140714913,
                "url": "https://finnhub.io/api/news?id=6e73db99eb90bdba0dcc6ce3b1fdb65dc67f9e26db4b15f806c34bbe7ef370f6",
                "image": "https://image.cnbcfm.com/api/v1/image/108326117-4ED4-NewsOPEN-062426.jpg?v=1782308764&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "CNBC brings you fast, accurate, and actionable business news and market updates.",
                "category": "company",
                "datetime": 1782294595,
                "headline": "Market Open: June 24, 2026"
              },
              {
                "id": 140713554,
                "url": "https://finnhub.io/api/news?id=a12d108ef365963472373d2c61c4a67b0be6f3fe6b1c74d0bd6a2de25283245d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/24/Pfizer-logo-on-building.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer shares are trading flat in Wednesday's premarket as traders weigh mixed Phase 3 trial headlines alongside a firmer overnight tape.",
                "category": "company",
                "datetime": 1782292825,
                "headline": "Pfizer Stock Trades Flat Following Mixed Phase 3 Lung Cancer Trial Data"
              },
              {
                "id": 140711652,
                "url": "https://finnhub.io/api/news?id=715b1f16fe7bb8c9cd178826cbdabb1821313cba3291961975e3f13deddff872",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "IBB, Novartis, Pfizer and Eli Lilly's have been highlighted in this Investment Ideas article.",
                "category": "company",
                "datetime": 1782289680,
                "headline": "Zacks Investment Ideas feature highlights: IBB, Novartis, Pfizer and Eli Lilly's"
              },
              {
                "id": 140708287,
                "url": "https://finnhub.io/api/news?id=ed2a7515e34cde5c66d377c382873c166dda91167b1532b844c155b8e660ecf0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Nike (NYSE:NKE) has appointed David M. Denton as its incoming Chief Financial Officer. Denton, who has held senior finance roles at Pfizer and Lowe's, is set to succeed current CFO Matthew Friend. The transition comes as Nike continues a multiyear turnaround and addresses operational challenges and skepticism about its execution. Nike, a major global sportswear and footwear company, is in the middle of a turnaround that includes operational adjustments and a renewed focus on execution. The...",
                "category": "company",
                "datetime": 1782256304,
                "headline": "Nike (NKE) Names David Denton CFO As Turnaround Pressure Builds"
              },
              {
                "id": 140708288,
                "url": "https://finnhub.io/api/news?id=b58ca5bde97bf59d788f643021141edc4a64053777e738b5959f60c388628893",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Nike announced a CFO transition and said fourth-quarter results remain on track, excluding a one-time tariff refund benefit.",
                "category": "company",
                "datetime": 1782252117,
                "headline": "NKE Stock Gains 2% After-Hours As Nike Names New CFO, Reaffirms Outlook — Retail Calls Leadership Transition ‘Promising’"
              },
              {
                "id": 140707051,
                "url": "https://finnhub.io/api/news?id=3d3316fb3b7db48ae82d23a56478369bc1fc020052c73070c24ba20ae3cd0f77",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "David Denton will join Nike Inc. as executive vice president and chief financial officer on Aug. 17, succeeding Matthew Friend.",
                "category": "company",
                "datetime": 1782250367,
                "headline": "Nike Discloses CFO Transition"
              },
              {
                "id": 140707052,
                "url": "https://finnhub.io/api/news?id=03cb6615165f50df66b0d7cd1a2515538a05bf9794dbb6cee78480c1a74cac2a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Don't wait until they recover to initiate positions.",
                "category": "company",
                "datetime": 1782247800,
                "headline": "2 High-Yield Dividend Stocks to Buy and Hold for a Decade"
              },
              {
                "id": 140706975,
                "url": "https://finnhub.io/api/news?id=f63b02dc0aac10355a9f7054c155d5f16ba173edcf55f023123366ee989c7462",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.",
                "category": "company",
                "datetime": 1782245820,
                "headline": "Biotech's Silent Resurgence (5-Year Base Breakout)"
              },
              {
                "id": 140706976,
                "url": "https://finnhub.io/api/news?id=40cea8fb275d861a3becf0bae0ceea497224f2f0a3b6e14fb3a81a0e9b67bd1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Before its fifty percent surge, the drug giant was repeatedly telling a story about its future that the market seemed to be ignoring.",
                "category": "company",
                "datetime": 1782244632,
                "headline": "The $50B Plan Merck Stock Was Broadcasting"
              },
              {
                "id": 140705695,
                "url": "https://finnhub.io/api/news?id=6a01d9d278fa39ca2d79c8515e3a2c62b3eeef294b015c074575d9b251cdf370",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On May 20, 2026, Pfizer Inc. (NYSE:PFE) CEO Albert Bourla said on “In Good Company” that pandemic-era urgency allowed an eight-month COVID vaccine timeline. He said that regulators and governments “reverted to more conservative” approaches afterward. […]",
                "category": "company",
                "datetime": 1782244492,
                "headline": "CEO Albert Bourla’s Take on Pfizer Inc. (PFE)"
              },
              {
                "id": 140704587,
                "url": "https://finnhub.io/api/news?id=38bcd9ac167f2f6b077abe8cdb9298c530469406740fc8f36cab4cd646da5bbe",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for the market.",
                "category": "company",
                "datetime": 1782237900,
                "headline": "Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session."
              },
              {
                "id": 140705696,
                "url": "https://finnhub.io/api/news?id=79e5c47eab31c81891c17cf547a353a9df6e1909c215933937b14753d50513ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Everyone is still arguing about Novo Nordisk (NYSE:NVO), the Danish obesity juggernaut whose GLP-1 franchise turned Wegovy and Ozempic into household names and dragged the entire pharma sector into a multi-year hype cycle. But here’s what you should actually be watching. The reality check has already started, and the numbers are uglier than the headlines ... Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait",
                "category": "company",
                "datetime": 1782237356,
                "headline": "Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait"
              },
              {
                "id": 140704346,
                "url": "https://finnhub.io/api/news?id=04252adc57ea78a16b7c6b8c5d11cf4c93efb789b48320fb047c7c8674e35151",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BILLERICA, Mass., June 23, 2026--Javelin Biotech today announced a landmark scientific publication, titled \"Interconnected multi-microphysiological systems and PBPK modeling for predicting human pharmacokinetics\", in the \"Breakthrough\" special issue of Lab on a Chip. The study details a liver-centric multi-tissue chip (MTC) platform designed to capture the complex pharmacokinetic (PK) profiles of small-molecule drugs.",
                "category": "company",
                "datetime": 1782236940,
                "headline": "Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform"
              },
              {
                "id": 140715317,
                "url": "https://finnhub.io/api/news?id=43e552595d833f9d134ce9cf78a462015b746753e08202fdbbc461e55bc0f159",
                "image": "https://image.cnbcfm.com/api/v1/image/108325793-1782248070009-gettyimages-2282993162-_88a8110_bi7xxdni.jpeg?v=1782248250&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "See which stocks are posting big moves after the bell.",
                "category": "company",
                "datetime": 1782235079,
                "headline": "Stocks making the biggest moves after hours: FedEx, Cerebras, KB Home & more"
              },
              {
                "id": 140702650,
                "url": "https://finnhub.io/api/news?id=8c6a3197022fd201e3b96106d01ea0567eb02a05356568195b374a133911d063",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) reported that its late stage lung cancer drug sigvotatug vedotin did not significantly improve overall survival in a pivotal Phase 3 trial. The trial compared sigvotatug vedotin to standard chemotherapy docetaxel in patients with metastatic non squamous non small cell lung cancer. The drug, part of the Seagen portfolio acquired for US$43b, showed a manageable safety profile and encouraging signals in a subset of patients, but the main efficacy goal was not met. For Pfizer,...",
                "category": "company",
                "datetime": 1782223586,
                "headline": "Pfizer (PFE) Lung Cancer Drug Misses Survival Goal In Phase 3 Trial"
              },
              {
                "id": 140702651,
                "url": "https://finnhub.io/api/news?id=7bb9a6d3db68d88b5a968774df7145716c16590972363e0780972ad2a3fe3ebf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, June 23, 2026--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 4, 2026. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2026 Performance Report, to be issued that morning.",
                "category": "company",
                "datetime": 1782223200,
                "headline": "Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts"
              },
              {
                "id": 140702600,
                "url": "https://finnhub.io/api/news?id=921a44a81749b4ef06389737c07a72d28c2efcae097c4e44898d2ffd854a0bb0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs docetaxel.",
                "category": "company",
                "datetime": 1782221400,
                "headline": "Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC"
              },
              {
                "id": 140703228,
                "url": "https://finnhub.io/api/news?id=8e79c669503d11407141d135d3ecf2d2ed9737814b31e80a39f5c9b0a2d97468",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220570668/image_2220570668.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Viatris Inc. hits a 52-week high, driven by a strong late-stage pipeline, but shares corrected on Effexor sales decline. Click for this VTRS update.",
                "category": "company",
                "datetime": 1782219355,
                "headline": "Viatris Soared 54%: Time To Be More Careful (Rating Downgrade)"
              },
              {
                "id": 140701544,
                "url": "https://finnhub.io/api/news?id=a6adaa88607ac07c90a4d4c94a030a9ff041e24a68d8cf640cbb9b4d9c335da1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer shares fell about 1.5% after sigvotatug vedotin failed to significantly improve survival in a late-stage lung cancer trial.",
                "category": "company",
                "datetime": 1782217535,
                "headline": "Pfizer Slides After Lung Cancer Drug Setback"
              },
              {
                "id": 140701432,
                "url": "https://finnhub.io/api/news?id=18f1e4cfd0598feca125bcf022d603484177055aad67802d5c5e9c2b913ef1ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep premium for its next act.",
                "category": "company",
                "datetime": 1782217249,
                "headline": "Should You Buy Or Sell AbbVie Stock At $230?"
              },
              {
                "id": 140704347,
                "url": "https://finnhub.io/api/news?id=853b195f2c96a8ac11009808f8107d9d55c46de2f32dd31b7d3fe6e3115a41c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.",
                "category": "company",
                "datetime": 1782216360,
                "headline": "Pfizer drug acquired in Seagen deal disappoints in lung cancer study"
              },
              {
                "id": 140702239,
                "url": "https://finnhub.io/api/news?id=2dbb24eb4ed647c8ae35735144917804502c042a575027fbf6aa7965998dbc45",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "https://news.bloomberglaw.com/us-law-week/pfizer-keeps-win-in-patent-lawsuit-aimed-at-paxlovid-antiviral",
                "category": "company",
                "datetime": 1782214340,
                "headline": "'Pfizer Keeps Win in Patent Lawsuit Aimed at Paxlovid Antiviral' - Bloomberg"
              },
              {
                "id": 140705213,
                "url": "https://finnhub.io/api/news?id=78ee1eac69eed68a40d6ed10f380fb328bd326dab827d15b66e1afb95c7bea1f",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/23/Shanghai--China--Nov--6--2022-Pfizer-Sig.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer's sigvotatug vedotin missed its Phase 3 OS goal in NSCLC but showed encouraging results in second-line patients.",
                "category": "company",
                "datetime": 1782210840,
                "headline": "Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients"
              },
              {
                "id": 140703548,
                "url": "https://finnhub.io/api/news?id=5a9e30e514e9e6a7a8a6cd34d9c021e169849760287ec9cb0946061abb89221e",
                "image": "https://image.cnbcfm.com/api/v1/image/108325393-17822191881782219185-46723283472-1080pnbcnews.jpg?v=1782219187&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the FDA's push to innovate, what to expect under new FDA leadership, future of the agency, and more.",
                "category": "company",
                "datetime": 1782205027,
                "headline": "Dr. Gottlieb on new FDA leadership: Having strong career leadership helps you get more policy done"
              },
              {
                "id": 140700953,
                "url": "https://finnhub.io/api/news?id=d9e536315b97c3074e2a19053e6928ca3cc7f6cc86cc2c744f0b11afce046908",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1928832415/image_1928832415.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Moderna, Inc. shifts beyond Covid with mRNA vaccines like mFlusiva, combo shots, and oncology catalysts. Click for more on MRNA stock prospects.",
                "category": "company",
                "datetime": 1782202884,
                "headline": "Moderna: The Comeback Is Now In Full Swing"
              },
              {
                "id": 140698074,
                "url": "https://finnhub.io/api/news?id=340b4044ad90483c6c58644e35cb65558737e6d780c4ccc854146002d4424102",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In the overall population, sigvotatug vedotin did not demonstrate a statistically significant improvement in overall survival compared with chemotherapy medicine docetaxel.",
                "category": "company",
                "datetime": 1782173282,
                "headline": "PFE Stock Reacts To Mixed Topline Results For Seagen-Origin Cancer Drug"
              },
              {
                "id": 140696234,
                "url": "https://finnhub.io/api/news?id=336ca9907ef5890a72220b7e5e8162bfaed51ff5a0ed916dff175c02bb999cbd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, June 22, 2026--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) who had received one or more lines of prior therapy.",
                "category": "company",
                "datetime": 1782160200,
                "headline": "Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer"
              },
              {
                "id": 140696168,
                "url": "https://finnhub.io/api/news?id=010a0c173a630e540494d5e2d1eab99fb6a756a2df8cfd552f03e2ce10329be0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE) just delivered Q1 2026 results that read like two different chapters of the same drug industry. Lilly is sprinting through an obesity gold rush. Pfizer is rebuilding after COVID and buying its way into the same race. Both beat estimates, but the businesses underneath could not feel ... Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow",
                "category": "company",
                "datetime": 1782158563,
                "headline": "Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow"
              },
              {
                "id": 140703670,
                "url": "https://finnhub.io/api/news?id=d560447c2ed49c61ad7c1fe00ea6c5c7cc97a6f006ba02b0e0ccba6be20ee622",
                "image": "https://image.cnbcfm.com/api/v1/image/108325149-17821648851782164882-46710721790-1080pnbcnews.jpg?v=1782164884&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "CNBC's Angelica Peebles joins 'Fast Money' with news of Pfizer's lung cancer drug trials.",
                "category": "company",
                "datetime": 1782150834,
                "headline": "Pfizer experimental lung cancer drug did not show survival benefit"
              },
              {
                "id": 140705214,
                "url": "https://finnhub.io/api/news?id=1849f8969eb1f417a296b9ddb005dbd8fe4c31ca3daf2ad0e6cc639bad63dbda",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6",
                "category": "company",
                "datetime": 1782146084,
                "headline": "Pfizer Says Phase 3 Sigvie‑002 Trial Of Sigvotatug Vedotin In Advanced NSCLC Did Not Meet Primary Endpoint Of OS Versus Docetaxel, Though Trends Favoured Antibody-Drug Conjugate In Patients With Only One Prior Line Of Therapy"
              },
              {
                "id": 140692651,
                "url": "https://finnhub.io/api/news?id=4c911d6cf7f8085fc6d947f57ba8856e9c5a2111e60a0ad58f72f4e65bc3cdfa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Zoetis has gotten torched over the last six months - since December 2025, its stock price has dropped 36.6% to $78.46 per share. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1782141799,
                "headline": "2 Reasons to Like ZTS and 1 to Stay Skeptical"
              },
              {
                "id": 140692527,
                "url": "https://finnhub.io/api/news?id=52cff7ec1098ae14406a3080b9e86f2a3739519ce6c8c3378d3ce8cb40cc2eb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's next act was well underway.",
                "category": "company",
                "datetime": 1782139584,
                "headline": "Merck Stock’s New Drugs Were Already Answering The Big Question"
              },
              {
                "id": 140692571,
                "url": "https://finnhub.io/api/news?id=fa11ca6a598f4408616c7eb67e33445ca802c1f24d5d17fac0c26f8ba28b1ed2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.",
                "category": "company",
                "datetime": 1782135300,
                "headline": "Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?"
              },
              {
                "id": 140691704,
                "url": "https://finnhub.io/api/news?id=ef546d5d629d354fb699b2392ffb8c3cbb60f594ace359008e68d913f479e5b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.",
                "category": "company",
                "datetime": 1782131160,
                "headline": "Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?"
              },
              {
                "id": 140691705,
                "url": "https://finnhub.io/api/news?id=d4b21e44b7b207a7c400e1149595716970f29f041c7abbdffa583714df0ab959",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The healthcare company is eyeing opportunities related to artificial intelligence, which it believes can enhance its operations.",
                "category": "company",
                "datetime": 1782130730,
                "headline": "Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead"
              },
              {
                "id": 140693158,
                "url": "https://finnhub.io/api/news?id=86585aa2f33c084e722ddce7eba2ffb69d2256433ea04aec214c6607d295f296",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/22/Pfizer-logo-on-building.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the finance seat.",
                "category": "company",
                "datetime": 1782124515,
                "headline": "Pfizer Stock Edges Lower Monday: What's Going On?"
              },
              {
                "id": 140692034,
                "url": "https://finnhub.io/api/news?id=865b9570ea14d8c83c150476046c7f244b91a195d4c74e1f47be8543a04a927f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398800679/image_1398800679.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Merck & Co., Inc. stock outlook: FDA approves Keytruda combo for kidney cancer as sales rise. Click here for this MRK update.",
                "category": "company",
                "datetime": 1782124439,
                "headline": "Merck's Oncology Engine Is Still Accelerating"
              },
              {
                "id": 140692220,
                "url": "https://finnhub.io/api/news?id=da0f27088ae0df413ebf4fac686d9f2ab5c033cb7baeba795f4d4c7131c78a49",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/22/Drug-Use-Surges-Among-Patients.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and specialty grocers win.",
                "category": "company",
                "datetime": 1782112557,
                "headline": "Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model"
              },
              {
                "id": 140688216,
                "url": "https://finnhub.io/api/news?id=2ffe8e459a245fa34362eb9cde375b61a54162105ca5330ba0c8fb45331bb84b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.",
                "category": "company",
                "datetime": 1782092100,
                "headline": "Could Pfizer Stock Be Your Ticket to Generational Wealth?"
              },
              {
                "id": 140685268,
                "url": "https://finnhub.io/api/news?id=d96abf3bf94a147bdb7a7b2142321323483cc1cf5ce22841a29c097bd4296175",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a beach, or asleep, and it lands in your account no matter what the broader market did that week. Earned income depends on showing up. Dividend income depends on a board of directors ... Own 500 Shares of Pfizer and JNJ and Here’s Your Annual Dividend Income",
                "category": "company",
                "datetime": 1782055806,
                "headline": "Own 500 Shares of Pfizer and JNJ and Here’s Your Annual Dividend Income"
              },
              {
                "id": 140684337,
                "url": "https://finnhub.io/api/news?id=101fe0fecef8aff9b8c2088f9a4323af8bfabd2b0fe52e9f6da6ad2fc8c46385",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued NYSE stocks to invest in. On June 18, Pfizer announced that Chief Financial Officer Dave Denton will step down on August 15 to pursue a new professional opportunity in the consumer goods industry. The company has appointed Cecile Guegan, currently Senior Vice President of Finance for […]",
                "category": "company",
                "datetime": 1782039171,
                "headline": "Pfizer (PFE) CFO Dave Denton to Step Down Effective August 15"
              },
              {
                "id": 140682844,
                "url": "https://finnhub.io/api/news?id=cca7b01d405fa8241ecd2c9f097ee318a8b33f3f355504bed7554f30dc38e42e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Novo Nordisk (NYSE:NVO)'s majority owner has launched a large pan European research program focused on obesity and cardiometabolic diseases. The initiative aims to speed up research, support startups, and feed potential candidates into Novo Nordisk's future drug pipeline. Pfizer is expanding efforts in obesity treatments, including plans for a first in class monthly GLP 1 therapy and broader clinical trials. Novo Nordisk is a central player in obesity and diabetes care, and this new...",
                "category": "company",
                "datetime": 1782011623,
                "headline": "Novo Nordisk (NYSE:NVO) Launches Pan European Obesity Research Push As Pfizer Closes In"
              },
              {
                "id": 140681710,
                "url": "https://finnhub.io/api/news?id=751df1bf725bd9926ce4afb628ba5d8c52f1cc9bbc6d2181d547771ef35cb069",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b pharmaceutical group is positioned, with value metrics and recent returns drawing closer scrutiny. See our latest analysis for Pfizer. Pfizer’s recent share price has softened, with the stock down 6.53% on a 90 day share price return basis, while the 1 year total shareholder return of 12.52% reflects a different experience for investors over a longer period. If Pfizer’s recent...",
                "category": "company",
                "datetime": 1781996843,
                "headline": "Pfizer (PFE) Stock Could Be 10% Undervalued After Recent Results"
              },
              {
                "id": 140681015,
                "url": "https://finnhub.io/api/news?id=922d1ee0357bc72cba465c5f026126ab7efaa0de930a5a46da88c4c295923d1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.",
                "category": "company",
                "datetime": 1781991300,
                "headline": "Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?"
              },
              {
                "id": 140677278,
                "url": "https://finnhub.io/api/news?id=f80d2a68c6aa8888feff9261652519ebe9dfdb657db4ab06fc4a7072b46e10ef",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2150646180/image_2150646180.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Explore Rigel Pharmaceuticals (RIGL) after a 35% pullback: valuation, Veppanu licensing, Tavalisse momentum, Q1 revenue growth, and FY2026 guidance—read...",
                "category": "company",
                "datetime": 1781941453,
                "headline": "A Look At The Transformation Around Rigel Pharmaceuticals"
              },
              {
                "id": 140670714,
                "url": "https://finnhub.io/api/news?id=430d336acd3c5b4a50da7d85fd2fcf7878f3a8a7463eb661721258f46601e66c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer shares fall after CFO Dave Denton announces his exit, though the company reaffirms 2026 guidance and maintains its strategic outlook.",
                "category": "company",
                "datetime": 1781879040,
                "headline": "PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed"
              },
              {
                "id": 140673091,
                "url": "https://finnhub.io/api/news?id=934c489592b5749f570db4ccc0a2a715a4724f749101cee70ce75cd6b0303934",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/19/Shenzhen--China--9-April--2025-Sign-Of-A.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "The Nasdaq 100 has tripled since 2020, but 10 mega-caps still trade below pre-Covid levels. Who's still underwater and why?",
                "category": "company",
                "datetime": 1781876605,
                "headline": "The Nasdaq 100 Has Tripled Since 2020, But These 10 Mega-Caps Are Still Underwater"
              },
              {
                "id": 140668607,
                "url": "https://finnhub.io/api/news?id=301f2345c23f938eec305d50352b197a2b7d65b5d344fca4e44aa3db1120717d",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_26_211b968776.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Tim Cook's warning that iPhone and Mac prices are going up because memory chips have become too expensive lit a fire under the storage names. Micron printed a record $1,133. Intel added 10% on the back of the Trump stake math. Accenture took an 18% beating on weak consulting bookings. Vance's cancelled trip to Switzerland nudged oil back above $80.",
                "category": "company",
                "datetime": 1781859781,
                "headline": "Apple's Price Warning Sends Memory Chips To A Record, Accenture Cracks 18%"
              },
              {
                "id": 140667013,
                "url": "https://finnhub.io/api/news?id=40038816fa54cd490942c62bfb04c763452a018b9dcd1c1764d125cf2b04ce44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.",
                "category": "company",
                "datetime": 1781830588,
                "headline": "How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story"
              },
              {
                "id": 140666631,
                "url": "https://finnhub.io/api/news?id=b65a89a175bc57a26cdb8820cd7ff4f3de192407b7468e0ead79b71a0fe37602",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.",
                "category": "company",
                "datetime": 1781825349,
                "headline": "Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook"
              },
              {
                "id": 140665981,
                "url": "https://finnhub.io/api/news?id=0b638c6ef191f5dbe4acd9d2334545c22003192c9ec27ab3ef212175c49ee56a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.",
                "category": "company",
                "datetime": 1781816249,
                "headline": "What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine?"
              },
              {
                "id": 140665156,
                "url": "https://finnhub.io/api/news?id=3dcd5a6560a680184504482fdd83e49944ba559a09ada99bf42393fcc8e71e7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) named an interim head of finance on Thursday as it announced the departure of Chief Fin",
                "category": "company",
                "datetime": 1781811668,
                "headline": "Pfizer Names Interim Finance Chief as CFO Quits; Drugmaker Affirms Full-Year Outlook"
              },
              {
                "id": 140665157,
                "url": "https://finnhub.io/api/news?id=05c2e2bbd42fa3ede9f04bc2b3e4951256ef8cbb69464d5a3578863fffe187bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In a filing with the Securities and Exchange Commission, Pfizer said Executive Vice President and Chief Financial Officer Dave Denton notified the company on June 16 that he will step down effective August 15.",
                "category": "company",
                "datetime": 1781810217,
                "headline": "PFE Stock Drops 3% On Surprise CFO Exit Despite Reaffirmed 2026 Guidance"
              },
              {
                "id": 140664465,
                "url": "https://finnhub.io/api/news?id=c09445703a003e6a5e03a1420917a9e30d4813da8d5892392b6d7e5a478205dc",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.",
                "category": "company",
                "datetime": 1781805900,
                "headline": "Thursday's session: most active stock in the S&P500 index"
              },
              {
                "id": 140664067,
                "url": "https://finnhub.io/api/news?id=57b08365bf8b68d202402b9d88ef7ef9662b8ea89a1f2adf2ff03ea34c6d236e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Cecile Guegan will become interim CFO on Aug. 16 while Pfizer searches for a successor.",
                "category": "company",
                "datetime": 1781805596,
                "headline": "Pfizer Shares Dip 1.5% as CFO Dave Denton Announces Exit"
              },
              {
                "id": 140664068,
                "url": "https://finnhub.io/api/news?id=252b4462acc50ce81befc2d32eabe45cc92eedf65874f305636ced5321e973b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Dave Denton will leave in August as Pfizer works through its post-COVID reset.",
                "category": "company",
                "datetime": 1781805551,
                "headline": "Pfizer CFO Exit Adds Pressure"
              },
              {
                "id": 140671475,
                "url": "https://finnhub.io/api/news?id=04c7499d656cafdfb442d13e8677cc5baa001c9ba76b98009765eeed5ac4b408",
                "image": "https://image.cnbcfm.com/api/v1/image/108324290-17818192661781819251-46629128711-1080pnbcnews.jpg?v=1781819265&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "Michael Yee, UBS global head of biotech research, joins 'Fast Money' to talk the biotech sector.",
                "category": "company",
                "datetime": 1781805250,
                "headline": "Surge in biotech being driven by M&A, says UBS's Michael Yee"
              },
              {
                "id": 140664069,
                "url": "https://finnhub.io/api/news?id=3c4ab0eb3c02d7f757af9dafaa3cd12d4785b7595220d82dbba28bfc1f163a1e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Healthcare stocks fell Thursday afternoon with the NYSE Healthcare Index decreasing 0.9% and the Sta",
                "category": "company",
                "datetime": 1781804098,
                "headline": "Sector Update: Healthcare Stocks Decline Thursday Afternoon"
              },
              {
                "id": 140664070,
                "url": "https://finnhub.io/api/news?id=6d9943dc90e818f99e50146e5d1610165de152f4f7714dcf9fcf8ff7f8cb4118",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Closed System Drug Transfer Devices Market size & share revenue was valued at approximately USD 1.47 Billion in 2025 and is expected to reach USD 1.58 Billion in 2026 and is expected to reach around USD 3.21 Billion by 2035, at a CAGR of 8.3% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are BD (Becton Dic",
                "category": "company",
                "datetime": 1781803800,
                "headline": "Global Closed System Drug Transfer Devices Market Size/Share Worth USD 3.21 Billion by 2035 at a 8.3% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)"
              },
              {
                "id": 140663699,
                "url": "https://finnhub.io/api/news?id=b8b92ffb860e5cc70e3d015eca0eeeb92133d41b1ca7679b54d793ea31dde42c",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.",
                "category": "company",
                "datetime": 1781802300,
                "headline": "These S&P500 stocks have an unusual volume in today's session"
              },
              {
                "id": 140664071,
                "url": "https://finnhub.io/api/news?id=ac8e3155a6d159bf7bffa4b44e569636101504ee5c3d7efc2727645aa312510c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer announced that Chief Financial Officer Dave Denton will leave the company in August to pursue an external opportunity. Senior Vice President Cecile Guegan has been appointed Interim CFO, effective upon Denton’s departure. The change affects Pfizer’s top financial leadership at a time when the company is focused on major pipeline investments and internal changes. For investors watching Pfizer (NYSE:PFE), this shift in financial leadership arrives with the stock trading at $25.92 and...",
                "category": "company",
                "datetime": 1781799560,
                "headline": "Pfizer (PFE) Names Cecile Guegan Interim CFO As Dave Denton Prepares To Exit"
              },
              {
                "id": 140664072,
                "url": "https://finnhub.io/api/news?id=ae7a4b815f223aab0bf7a22942a2eb13065d4218086369efe2d3f55c4451944f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Market Catalyst Host Julie Hyman breaks down today's Trending Tickers, giving us the latest on Accenture (ACN), Pfizer (PFE), and Kroger (KR).",
                "category": "company",
                "datetime": 1781798471,
                "headline": "Why Accenture, Pfizer, and Kroger are moving today"
              },
              {
                "id": 140663901,
                "url": "https://finnhub.io/api/news?id=e33466a2619e50c8a1401ab4bee09d9172db051a5ce536efb8c80692bc7be3a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "All three major US stock indexes rose in midday trading Thursday as investors assessed the signing o",
                "category": "company",
                "datetime": 1781798144,
                "headline": "Top Midday Stories: US, Iran Seal Memorandum to Reopen Hormuz; Intel Gains After Trump Cites Apple Chip Partnership"
              },
              {
                "id": 140663154,
                "url": "https://finnhub.io/api/news?id=ed24b4beafbfc166200f2cdc5d6f4785e883c7ea8e905162c48bc84fd2478d32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the BIO International Convention in San Diego, California, taking place on June 22-25, 2026, it stated […] The post VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1781793250,
                "headline": "VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026"
              },
              {
                "id": 140663080,
                "url": "https://finnhub.io/api/news?id=d4cdbd58ea79149c547e247836d9bf4745bceee1a7bb818a65ea07baf93714a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.",
                "category": "company",
                "datetime": 1781791860,
                "headline": "Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?"
              },
              {
                "id": 140665496,
                "url": "https://finnhub.io/api/news?id=d4abe94733c79806466542b322722f95d90ccdcf1945b38e793643d1a4fca694",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "https://www.sec.gov/ix?doc=/Archives/edgar/data/78003/000007800326000087/pfe-20260618.htm",
                "category": "company",
                "datetime": 1781789033,
                "headline": "Pfizer Reaffirms FY26 Adjusted EPS Range $2.80 to $3, Revenue Range $59.5B - $62.5B"
              },
              {
                "id": 140662532,
                "url": "https://finnhub.io/api/news?id=5eb02fcb393a894cb29489872e83ff71eba35f07da6edb8a820775ec8d10e6c5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) shares edged lower on Thursday after the pharmaceutical giant revealed that Chief Financial Officer Dave Denton will step down from his position and leave the company in August.",
                "category": "company",
                "datetime": 1781787591,
                "headline": "Pfizer Shares Slip Following CFO Transition Announcement"
              },
              {
                "id": 140663130,
                "url": "https://finnhub.io/api/news?id=c17fe083e38c20a2c0c6b0c283b9582ea59c3d593694f70299817c6311a6de1e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.",
                "category": "company",
                "datetime": 1781787420,
                "headline": "GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections"
              },
              {
                "id": 140665497,
                "url": "https://finnhub.io/api/news?id=ef0464a6790db3e82b75eb3ba0186ab333be17c4a9e7e24099979d765f032eeb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/18/Pfizer-Covid-shot.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer shares are slipping Thursday after it announced that Chief Financial Officer Dave Denton will leave the organization.",
                "category": "company",
                "datetime": 1781787257,
                "headline": "Pfizer Stock Drops Today As CFO Steps Down In August"
              },
              {
                "id": 140671446,
                "url": "https://finnhub.io/api/news?id=7c53d213870ff61f259c444555ed8b6134043c19627bef7efe358a914e74002b",
                "image": "https://image.cnbcfm.com/api/v1/image/108259843-1769808873890-gettyimages-2259118265-_73a8666_welxx1ya.jpeg?v=1769808991&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "Here are the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1781786506,
                "headline": "Stocks making the biggest moves midday: Sandisk, Intel, Enphase Energy, Accenture, Exxon Mobil & more"
              },
              {
                "id": 140662533,
                "url": "https://finnhub.io/api/news?id=d2aca68b4a3e973e17f9757a1d2156a1da98b84a045d2bfb8341db3afe25818b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Cecile Guegan will serve as interim CFO starting August 16 while Pfizer searches for a permanent replacement",
                "category": "company",
                "datetime": 1781785842,
                "headline": "Pfizer CFO Dave Denton stepping down in August 2026"
              },
              {
                "id": 140662534,
                "url": "https://finnhub.io/api/news?id=d50d3137dd82af4d89efaa721b425a5abdc7d69b737146f7f75aa818ee26aaf0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Investing.com - U.S. stock futures ticked higher on Thursday, as the signing of an interim Middle East peace deal helped ease concerns sparked by the Federal Reserve’s hawkish policy outlook.",
                "category": "company",
                "datetime": 1781785363,
                "headline": "FreeCast surges premarket; Accenture, Novocure slide"
              },
              {
                "id": 140664292,
                "url": "https://finnhub.io/api/news?id=2c76d72ef28c16019c44065fa3981f584a4833b6c01bce3b7b27d649bc7883c8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/18/Merck.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "FDA Expands Merck CAPVAXIVE Use To At-Risk Children And Adolescents Aged 2-17 Following Positive Phase 3 STRIDE-13 Data.",
                "category": "company",
                "datetime": 1781782166,
                "headline": "FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens"
              },
              {
                "id": 140663171,
                "url": "https://finnhub.io/api/news?id=4d7fc22ee1f9237dd7ba3961d9e23c2043c1a49d2eae0059030e6a20596bd429",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GSK deal paid dividends.",
                "category": "company",
                "datetime": 1781780100,
                "headline": "Pfizer CFO to step down; Denali sells a regulatory fast-pass"
              },
              {
                "id": 140662061,
                "url": "https://finnhub.io/api/news?id=5ccd08df1b5f3e58f807fdac3276ceb142739f04ffa3154bfea94bf56252ef8b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, June 18, 2026--Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted. The company has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, while Pfizer conducts a comprehensive",
                "category": "company",
                "datetime": 1781779500,
                "headline": "Pfizer Announces Chief Financial Officer Transition"
              },
              {
                "id": 140663172,
                "url": "https://finnhub.io/api/news?id=1e9a73194a9c59253b52fa6f1a26bc15408ef541fc035bb4c11f200728f4d915",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Dave Denton joined Pfizer in 2022 from Lowe’s Companies and is leaving for an unspecified “professional opportunity” in consumer goods, the company said.",
                "category": "company",
                "datetime": 1781778248,
                "headline": "Pfizer CFO departs for consumer goods sector"
              },
              {
                "id": 140661746,
                "url": "https://finnhub.io/api/news?id=8f2de543a98d8bd2fd56150b5160755140c95b310069f6965f0ce5d7594ccc1e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "STAMFORD, Conn., June 18, 2026--State Street, Pfizer, Siemens, Merck KGaA, Deutsche Bank, Fresenius and more will discuss ROI at the ISG AI Impact Summit, June 22–23 in Frankfurt.",
                "category": "company",
                "datetime": 1781773200,
                "headline": "ISG Event to Explore How Enterprises Are Turning AI Investments Into Measurable Business Value"
              },
              {
                "id": 140671552,
                "url": "https://finnhub.io/api/news?id=a320e5db4734a93779cf5fc9128d7e420098a8277c8c64841e5bc3f694043232",
                "image": "https://image.cnbcfm.com/api/v1/image/108282729-1774438918590-gettyimages-2267765199-AA_25032026_2709468.jpeg?v=1774438944&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "These are the stocks posting the largest moves in the premarket.",
                "category": "company",
                "datetime": 1781768595,
                "headline": "Stocks making the biggest moves premarket: Intel, SpaceX, Micron, Carnival & more"
              },
              {
                "id": 140661855,
                "url": "https://finnhub.io/api/news?id=5e7923cb7cbb8ebf12e23d75ac6ca50da2671a001d9cc1305a302d493fbf026a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2265088343/image_2265088343.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "ABIVAX plans NDA submission for obefazimod in Q4 2026, with Crohn’s disease Phase 2b data delayed to mid-2027. Learn why ABVX stock is a strong sell.",
                "category": "company",
                "datetime": 1781765611,
                "headline": "Abivax: Safety Signals Loom Ahead Of The NDA Submission"
              },
              {
                "id": 140665499,
                "url": "https://finnhub.io/api/news?id=e4e78b4f4743b8496323ddaff3495e50c9cc3a6f645cec9def8190d7ee36a57d",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical",
                "category": "company",
                "datetime": 1781765283,
                "headline": "Pfizer Says CFO Dave Denton To Step Down On August 15; Appoints Cecile Guegan, Currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim CFO, Effective August 16"
              },
              {
                "id": 140656174,
                "url": "https://finnhub.io/api/news?id=2aa3c28a6316d21cd0b3a250dbcd7a34faab4f462d8a0077eef69088034ae1a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.",
                "category": "company",
                "datetime": 1781720514,
                "headline": "Eli Lilly Stock's Trillion-Dollar Question"
              },
              {
                "id": 140654833,
                "url": "https://finnhub.io/api/news?id=0af54b09cc456b697d54b1cbe3268af507e3f7ce906b018927f8e52bf8c00d41",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.",
                "category": "company",
                "datetime": 1781716091,
                "headline": "The Number That Could Test Johnson & Johnson Stock"
              },
              {
                "id": 140654836,
                "url": "https://finnhub.io/api/news?id=75650634439443a1b3278415e11c94f5fd9a43ed9188da817a87e5cdb95ed5fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.",
                "category": "company",
                "datetime": 1781711865,
                "headline": "Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That Vanished"
              },
              {
                "id": 140654940,
                "url": "https://finnhub.io/api/news?id=9198bab85f055bca7466b78674cc28aba4ab34ada275ec6f727ca2b4d9896aa1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money. On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. (NASDAQ:GPCR) from $100 to $70, which still leads to an adjusted upside potential of more than 61%. The firm upheld its Buy rating on the […]",
                "category": "company",
                "datetime": 1781711738,
                "headline": "H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)"
              },
              {
                "id": 140655934,
                "url": "https://finnhub.io/api/news?id=e328d1b1bdbcf12e914d4403d25fd41e0c0cef8c23cd60912819b779c2208e37",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "2026-06-17. The following slide deck was published by Pfizer Inc.",
                "category": "company",
                "datetime": 1781711016,
                "headline": "Pfizer Inc. (PFE) Discusses New Phase IIb Data and Development Plans for Berobenatide GLP-1 Receptor Agonist in Obesity - Slideshow"
              },
              {
                "id": 140655757,
                "url": "https://finnhub.io/api/news?id=36aafa1a4a797bb30f02c5f711acd2cc1f1a03f3e3167e8e3b5558cfdda9f456",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Pfizer Inc. buy case: 55%+ upside in 2 years from pipeline catalysts, undervalued earnings & 6.7%+ dividend yield—read key risks & targets. Click for a PFE update.",
                "category": "company",
                "datetime": 1781709243,
                "headline": "Pfizer: Why I'm Still Expecting A Massive Rebound"
              },
              {
                "id": 140654036,
                "url": "https://finnhub.io/api/news?id=ecb9912c7557593bf99d72b00451ceb6482f8713f92f7c48acef67bfc0933ede",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195556307/image_2195556307.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Explore Eli Lilly and Company's surge, M&A strategy, and pipeline diversification beyond tirzepatide—plus 2030 revenue/valuation targets. Click for this LLY update.",
                "category": "company",
                "datetime": 1781701090,
                "headline": "Eli Lilly: Pharma With Unstoppable Momentum Targets Pain With Latest M&A Deal"
              },
              {
                "id": 140652552,
                "url": "https://finnhub.io/api/news?id=5b91f59fe1c78d22f0d07ac9c504becd794af72a127d1bca868d6352c41a455f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "STORY: Big pharma is receiving pushback from European capitals on drug pricing. So they’re turning to a playbook that brought them success in the UK.Making threats to pull investment plans to pressure policymakers. The industry notched a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs. The latest nation to face pressure is Germany, which has been debating legislation to tighten spending on medicines. A Reuters European Pharma correspondent Maggie Fick said pressure in the last week has ramped up. \"The CEO of Pfizer wrote a letter to the German chancellor warning that their future investments in the country may be at risk over these proposed changes to pricing laws.\"Meanwhile, AstraZeneca warned that it may not launch new medicines in Germany if these changes go ahead.Earlier in June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation. This bid to cap costs has centered Germany in a broader tussle between drugmakers and European governments that began several months ago.That tension has been sharpened by the impact on Europe of U.S. President Donald Trump's pricing push.This aims to tie prescription medicine prices in the lucrative U.S. market to ​lower prices elsewhere, including in Europe.Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices elsewhere.",
                "category": "company",
                "datetime": 1781697632,
                "headline": "Big pharma taps UK playbook to pressure Europe on drug prices"
              },
              {
                "id": 140650018,
                "url": "https://finnhub.io/api/news?id=d45534a979700b57977c1d699bdc5e1438ef0fe59ff33f404037ada10be1c49e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer and SINOPHARM have entered into a new partnership to promote antifungal drug Diflucan in China. The collaboration also includes plans to work together on future Pfizer product launches in the Chinese market. The agreement focuses on supply chain optimization, resource integration, and improving commercial execution across China. Pfizer (NYSE:PFE) is using this new agreement with SINOPHARM to deepen its presence in one of the world’s most important pharmaceutical markets. With the...",
                "category": "company",
                "datetime": 1781662237,
                "headline": "Pfizer (PFE) Expands China Partnership With SINOPHARM Around Diflucan And Future Launches"
              },
              {
                "id": 140649580,
                "url": "https://finnhub.io/api/news?id=ae7b668d55440a253dac0b3035c32afc96bb0c1d934f668e5e287108357a66dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global GLP-1 Receptor Agonist Market size & share revenue was valued at approximately USD 28.7 Billion in 2025 and is expected to reach USD 34.2 Billion in 2026 and is expected to reach around USD 95.3 Billion by 2035, at a CAGR of 12.1% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Novo Nordisk A/S, Eli Lill",
                "category": "company",
                "datetime": 1781649000,
                "headline": "[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)"
              },
              {
                "id": 140648902,
                "url": "https://finnhub.io/api/news?id=4c197a486d910424162619664c72c1a087d13e101b407d18dd07d5016fa11c34",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and satisfaction of other customary closing conditions. Rigel previously announced it entered into an exclusive, global license agreement with Arvinas, Inc. (Arvinas) an",
                "category": "company",
                "datetime": 1781640060,
                "headline": "Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)"
              },
              {
                "id": 140647785,
                "url": "https://finnhub.io/api/news?id=dd33f6b1d852e88ea246f52bbf583b74983a55f7a3cfa64a7896227bc17d03ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes Moderna stock to +94% year to date (YTD), easily the best performance in the major vaccine cohort. By comparison, Pfizer (NYSE:PFE) stock is ... Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?",
                "category": "company",
                "datetime": 1781637675,
                "headline": "Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?"
              },
              {
                "id": 140647869,
                "url": "https://finnhub.io/api/news?id=2d2a6c6eda13d9014a3e1d1db1e81e6dbba2c702aceaeecf121732bd62b1c230",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "CEO Doustdar expects to submit oral Wegovy for Chinese regulatory approval in \"a few months\"",
                "category": "company",
                "datetime": 1781635944,
                "headline": "Novo Nordisk to File Oral Wegovy in China"
              },
              {
                "id": 140649079,
                "url": "https://finnhub.io/api/news?id=b1c08892abde49ad43d9b3bcc1f7bad77bcd46524c8c6451ade52f3efe09e38a",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act ",
                "category": "company",
                "datetime": 1781625892,
                "headline": "Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The Agreement"
              },
              {
                "id": 140644889,
                "url": "https://finnhub.io/api/news?id=52ee3b50655b71dfd8b2294e695469a2dcc3239e6ee8e72d2db07c8b891a5276",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The move could expand Novo's reach in a key obesity-drug market.",
                "category": "company",
                "datetime": 1781613422,
                "headline": "Novo Seeks China Approval for Wegovy Pill"
              },
              {
                "id": 140645969,
                "url": "https://finnhub.io/api/news?id=42dce7cf67e671ab5e2a97957890145eee58f933c5a9029ea266c1b9edfba323",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose",
                "category": "company",
                "datetime": 1781599853,
                "headline": "FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose"
              },
              {
                "id": 140644113,
                "url": "https://finnhub.io/api/news?id=6a5a42cfb9a3e55a70596d11f311f041a61116b08fe0424c43ccc59eed09abdc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer, Altria, Newmont, Koil Energy and Stratus Properties are featured for their growth drivers, challenges and recent stock performance.",
                "category": "company",
                "datetime": 1781598540,
                "headline": "The Zacks Analyst Blog Highlights Pfizer, Altria, Newmont, Koil Energy and Stratus Properties"
              },
              {
                "id": 140640498,
                "url": "https://finnhub.io/api/news?id=7ffaa2903830f2b5deeb11785128c86a19e36ee5c9f71984bffb0983dac53d43",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Altria Group, Inc. (MO) and Newmont Corp. (NEM), as well as two micro-cap stocks, Koil Energy Solutions, Inc. (KLNG) and Stratus Properties Inc. (STRS).",
                "category": "company",
                "datetime": 1781554500,
                "headline": "Top Research Reports for Pfizer, Altria & Newmont Corp."
              },
              {
                "id": 140638792,
                "url": "https://finnhub.io/api/news?id=ab53a6418b76d99a492dc8c3ad5d4331d5d95b499c9c87c8adafd5a6256ae7c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's business may be in better shape than investors think.",
                "category": "company",
                "datetime": 1781544000,
                "headline": "Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit Growth"
              },
              {
                "id": 140638957,
                "url": "https://finnhub.io/api/news?id=13d18289dcf12dc1afd9db396516d121c4929434ad5624c11233fbac55f910a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "DelveInsight's EGFR Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Non-small cell lung cancer (NSCLC), Colorectal cancer (CRC), Head and neck cancer (HNC), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging EGFR in",
                "category": "company",
                "datetime": 1781541060,
                "headline": "EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight"
              },
              {
                "id": 140637911,
                "url": "https://finnhub.io/api/news?id=34c50db6c012e281a570b6af876f88fe84a025c86611854903a3f549ad77be5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.",
                "category": "company",
                "datetime": 1781532240,
                "headline": "Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?"
              },
              {
                "id": 140638020,
                "url": "https://finnhub.io/api/news?id=65ddec0237044c0e1533f22b99b41313c2d2a5e17c237f0caddf9ae5fdcb4da2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1781528404,
                "headline": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know"
              },
              {
                "id": 140636539,
                "url": "https://finnhub.io/api/news?id=f8df0909ad865f3b772509dee226fa0a8ef2ede0d05da0f802d87353e9137472",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "KIGALI, Rwanda and SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) -- Bio Usawa, a biotechnology company dedicated to expanding access to high-quality biologic medicines across Africa, today announced the appointment of Dr. Aida Habtezion to its Board of Directors. Her appointment marks a significant milestone as the company accelerates its efforts to build sustainable biotechnology manufacturing capacity on the continent and improve access to life-changing therapies for patients across Africa. Dr",
                "category": "company",
                "datetime": 1781510400,
                "headline": "Bio Usawa Appoints Dr. Aida Habtezion, Former Chief Medical Officer at Pfizer, to its Board of Directors"
              },
              {
                "id": 140634703,
                "url": "https://finnhub.io/api/news?id=e52812f95228545db83d7d658f6a42e206308c126dc56b03a8ed96426b0c0a02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) released detailed Phase 2b results for berobenatide, its investigational monthly GLP-1 receptor agonist for obesity. The data show proof of concept with favorable tolerability and low reported adverse events in the trial setting. Pfizer has started Phase 3 trials and outlined a broader clinical program for berobenatide as part of its late-stage obesity pipeline. For investors tracking NYSE:PFE, this update offers a clearer view of how Pfizer is positioning itself in the...",
                "category": "company",
                "datetime": 1781485798,
                "headline": "Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation"
              },
              {
                "id": 140631625,
                "url": "https://finnhub.io/api/news?id=8937fd45928381a6d80f71affebd41492f8dcfd7350b1017c8556676053e617e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/926069614/image_926069614.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Holiday-shortened Wall Street week preview: Fed June rate decision & Warsh presser, retail sales, G7, earnings, and triple witching risks.",
                "category": "company",
                "datetime": 1781417163,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 140631040,
                "url": "https://finnhub.io/api/news?id=1258b0acc5bfb9b6e91744eee25c9dc4471dc1c5b0703a9979179cb01cdc0136",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "With an annual dividend yield of 6.57%, Pfizer Inc. (NYSE:PFE) is included among the 12 High Yield Fortune 500 Stocks to Buy Now. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company’s global portfolio includes medicines and vaccines, as well as many of the world’s […]",
                "category": "company",
                "datetime": 1781415163,
                "headline": "Pfizer (PFE) Upgraded at RBC Capital. Here is Why"
              },
              {
                "id": 140627750,
                "url": "https://finnhub.io/api/news?id=93cd589845c5688e6e9b71a89cf72bc83d23d66fddfdb7c6857d39d58f6e40ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Passive income arrives while you sleep, commute, or vacation. That appeal drives dividend investing: a paycheck every quarter regardless of market conditions or work hours. Layoff announcements have rattled white-collar industries through the first half of 2026, and essentials costs climb faster than most household raises. Building a cash-flowing portfolio is one of the few ... 3 Stocks With a Yield Over 6% For Passive Income Investors",
                "category": "company",
                "datetime": 1781364372,
                "headline": "3 Stocks With a Yield Over 6% For Passive Income Investors"
              },
              {
                "id": 140626824,
                "url": "https://finnhub.io/api/news?id=968fb5d95d0f47092c0a5931d3a98094cfdb99149f1e0e2092c8000e44f91b32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) is one of the 7 Best Longevity Stocks to Buy Now. On June 8, 2026, Pfizer Inc. (NYSE:PFE) announced that the U.S. FDA approved an expanded indication for Hympavzi to include patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients with or without inhibitors. Hympavzi is […]",
                "category": "company",
                "datetime": 1781347227,
                "headline": "Pfizer (PFE): The Best Longevity Stock to Buy Now"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 249,
            "discarded_article_count": 217
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 11.8,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0.5,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.5,
            "vcp_reason": "升放量(近10日3日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 46054996.666666664,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 54570380,
              "avg_vol_20": 51813940,
              "avg_vol_30": 46054996.666666664,
              "range_pct_10": 0.0614432989690721,
              "range_pct_20": 0.11835051546391742,
              "range_pct_30": 0.12041237113402055,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.184895971113956,
              "dist_to_20d_high": 0.08456021140052845,
              "down_shrink_days": 1,
              "breakout_level_20d": 26.49,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.5102739726027394
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.6008247422680415,
              "turnoverUsdM": 696.473192,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.PFE",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 22.9886,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.2,
            "take_profit_price": 25.4625,
            "target_multiplier": 1.6,
            "technical_strength": 1.45,
            "take_profit_percent": 5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.201649484536083,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 0.6307,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.6
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -55.14
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.3124
    },
    "kdj": {
      "d": 30.05,
      "j": 66.45,
      "k": 42.18,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 28.33
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -356152956,
      "recentSlope": 2722504.4,
      "previousSlope": -32600500
    },
    "rsi": 33.47,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 24.5044,
      "position": "SAR喺價上",
      "distancePct": 1.05,
      "previousTrend": "下降"
    },
    "ma50": 25.484,
    "macd": {
      "macd": -0.48688995723772877,
      "trend": "看跌",
      "signal": -0.47431692498197797,
      "histogram": -0.012573032255750793
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 24.7552,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.56,
      "score": 2,
      "avgVolume": 51486307,
      "currentVolume": 28720544
    },
    "derived": {
      "ma20": 24.7845,
      "ma50": 25.484,
      "prevClose": 24.05,
      "avgVolume10": 49746174,
      "avgVolume20": 51486307,
      "changePercent": 0.83,
      "avgVolumeForScore": 51486307
    },
    "ma_cross": {
      "ma20": 24.7845,
      "ma50": 25.484,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 24.857,
      "prevMa50": 25.5348,
      "spreadPct": 2.74,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 23.027,
      "upper": 26.542,
      "position": "中間"
    },
    "rsi_short": 54.7,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.56
    }
  }
}

{
  "close": 24.25,
  "volume": 28720544,
  "changePercent": 0.83
}